Mutations in PI(3,5)P2 Signaling and Neurodegeneration in Mouse and Human. by Chow, Clement Y.
MUTATIONS IN PI(3,5)P2 SIGNALING AND NEURODEGENERATION IN 











A dissertation submitted in partial fulfillment 
of the requirements for the degree of 
Doctor of Philosophy 
(Human Genetics) 














 Professor Miriam H. Meisler, Chair 
 Professor Sally A. Camper 
 Professor David Ginsburg 
 Associate Professor David C. Kohrman 











































To my wife, Candace 
 




 I would first like to thank my mentor, Miriam Meisler.  She is the 
consummate scientist.  Miriam is inquisitive and interested in a wide range of 
topics.  This trait has taught me to always ask the right questions and be 
skeptical of conclusions that are not supported by data.  Miriam’s unending 
desire to make each oral presentation perfect drove me to improve my own skills.  
I came to this lab without any public presentation skills, but I am now greatly 
improved in my presentation abilities, a skill crucial for a successful scientific 
career.  Miriam is a perfectionist when it comes to writing and always encouraged 
me to do the same.  I will continue to strive to perfect my writing abilities.  I came 
to the lab wanting to positionally clone a mouse mutant.  I told Miriam that I would 
stay in the lab if she allowed me to do so.  She was supportive and excited from 
the beginning, allowing me to pursue a project with an unknown future.  This 
allowed me to learn, first hand, many aspects of genetics that such a project 
provides.  Her scientific guidance was invaluable, as it led to many new 
discoveries that have allowed me to publish great papers, and attend and 
present at the best scientific meetings.  I thank Miriam for her guidance during 
my graduate career and I will always look to her as a role model. 
 
I would also like to thank all the members of the Meisler lab, both past and 
present.  Everyone has been helpful with their technical advice and their scientific 
 iv 
conversations.  I am indebted to Susannah Cheek, Sarah Bergren and Adrienne 
Grant for their assistance in mouse genotyping, an often thankless job.  Julie 
Jones was amazing in her technical knowledge and helped me improve my 
experiments every step of the way.  I would like to thank Maja Adamska for 
initially detecting pale tremor in our mouse room.  This initial observation led to 
all the experiments described in this thesis.  Jennifer Kearney and Viive Howell 
were extremely helpful with their scientific discussions and career advice.  
Though they have only been with the lab for a short time, I would like to thank 
Guy Lenk and Cole Ferguson for showing interest in my project.  I leave the Fig4 
project in your hands.  Lois Weisman and her lab have been instrumental in the 
success of my thesis.  They provided the expertise and technical skills that 
greatly improved many aspects of each project.  I specifically would like to thank 
Yanling Zhang, Emily Kaufman, Sergey Zolov, and Natsuko Jin for their 
contributions of crucial data to my thesis.  I would also like to thank all the 
students in Human Genetics and other departments that have supported me.  My 
thesis committee, Sally Camper, David Ginsburg, David Kohrman, and Geoff 
Murphy, have all been very helpful with their advice and support.  I especially 
thank them for taking the time to speak with me about specific aspects of my 
project and taking the time to give me career advice.  I thank my wife Candace 
for all the sacrifices she has made to be with me.  Her support, love and patience 
have been invaluable to my success.  Finally, the success of my thesis project 
would not have been possible without the strength I receive from my faith in God. 
 v 
TABLE OF CONTENTS 
DEDICATION ....................................................................................................... ii 
ACKNOWLEDGEMENTS ................................................................................... iii 
LIST OF FIGURES.............................................................................................. vi 
LIST OF TABLES ............................................................................................. viii 
CHAPTER 
 
I INTRODUCTION ....................................................................................... 1 
 
II MUTATION OF FIG4 CAUSES NEURODEGENERATION IN THE PALE 
TREMOR MOUSE AND PATIENTS WITH CMT4J................................. 21 
Abstract......................................................................................... 21 
Results and Discussion................................................................. 22 
Materials and Methods.................................................................. 42 
Acknowledgements ....................................................................... 48 
Notes............................................................................................. 49 
 
III A TRANSGENIC MOUSE MODEL OF CMT4J....................................... 50 
Introduction ................................................................................... 50 
Results .......................................................................................... 51 
Discussion..................................................................................... 55 
Materials and Methods.................................................................. 70 
Acknowledgements ....................................................................... 73 
 
IV MUTATION OF THE PI(3,5)P2 REGULATOR VAC14 CAUSES A 
LETHAL NEUROLOGICAL DISORDER IN THE INGLS MOUSE 
MUTANT.................................................................................................. 74 
Introduction ................................................................................... 74 
Results .......................................................................................... 77 
Discussion..................................................................................... 80 
Materials and Methods.................................................................. 95 
Acknowledgements ....................................................................... 98 
Notes............................................................................................. 99 
 




LIST OF FIGURES 
Figure 
1-1. The structure of a phosphoinositide molecule........................................ 16 
1-2. Interconversion of phosphoinositides..................................................... 17 
1-3. PI3P and PI(3,5)P2 label endosomes and lysosomes ........................... 18 
1-4. Schwann cells and axons....................................................................... 19 
2-1. Phenotypes and genetic mapping of pale tremor mice .......................... 32 
2-2. Fig4 is mutated in the pale tremor mice ................................................. 33 
2-3. Mouse Fig4 has conserved function....................................................... 34 
2-4. Neuropathology in pale tremor mice ...................................................... 35 
2-5. Pathological abnormalities in peripheral nerves..................................... 36 
2-6. Brain degeneration in pale tremor mice ................................................. 37 
2-7. Pigment and spleen abnormalities in pale tremor mice.......................... 38 
2-8. Mutations of FIG4 in patients with Charcot-Marie-Tooth disease........... 39 
2-9. Haplotypes of CMT patients with mutations in FIG4 .............................. 40 
2-10. Yeast Fig4Ile>Thr is defective in activation of kinase Fab1/PIKfyve ........ 41 
3-1. Structure of I41T transgene ................................................................... 60 
3-2. Expression of Fig4 in transgenic lines.................................................... 61 
3-3. I41T transgene experimental breeding scheme ..................................... 63 
3-4. Reduced body weight of Fig4-/- mice is rescued by the I41T transgene. 64 
3-5. Normal neuromuscular ability of Fig4-/-, Tg+ mice .................................. 65 
 vii 
3-6. Lethality of Fig4-/- is rescued by I41T transgene..................................... 66
3-7. CMT4J mice have pale coat color.......................................................... 67 
3-8. A FIG4 missense variant in a CMT patient............................................. 68 
3-9. R905C is a SNP in mouse train WSB/EiJ .............................................. 69 
4-1. A new allele of Vac14 in the ingls mouse............................................... 85 
4-2. ingls (Vac14L156R) does not complement the Vac14 null allele............... 86 
4-3. Hydrocephalus in Vac14L156R/L156R and Vac14L156R/- brain....................... 87 
4-4. Neurodegeneration in brain of ingls (Vac14L156R/L156R) mice................... 88 
4-5. Neurodegeneration in brain of Vac14L156R/- mice.................................... 89 
4-6. No degeneration in DRGs and motor neurons in Vac14L156R/L156R 
Vac14L156R/- mice.................................................................................... 90 
 
4-7. Vac14L156R causes a defect in the synthesis of PI(3,5)P2 ...................... 91 
4-8. Yeast Vac14L>R fails to interact with Fab1.............................................. 92 
4-9. Vac14 functional protein domains .......................................................... 94 
5-1. PI(3,5)P2 pathway in yeast and mammals........................................... 123 
 viii 
LIST OF TABLES 
Table 
1-1. CMT subtypes and genetic loci that account for ~85% of CMT.............. 15 
1-2. CMT subtypes with mutations in phosphoinositide-related genes.......... 20 
3-1. Inheritance of transgene in Tg705 and Tg721 is consistent with one 
insertion site........................................................................................... 62 
 
4-1. Comparison of Fig4 and Vac14 mutant mice ......................................... 93 
5-1. Missense mutations of yeast Fig4........................................................ 124 
5-2. Missense mutations of yeast Fab1....................................................... 125 
5-3. Mutation screens with negative results ................................................ 126 
5-4. Novel nonsynonymous and protein truncating variants identified in 
human FIG4......................................................................................... 127 
 










 Mouse genetics is an important tool for identifying genes involved in 
human disease and for understanding their biological roles.  The mouse is well 
suited for this purpose because of genetic tools that have been developed, its 
short life span, and its similar physiology to humans.  Forward genetics is an 
unbiased, phenotype driven method to identify novel disease genes.  Forward 
genetics ensures that the disease gene identified is involved in the phenotype 
being studied.  Reverse genetics is a gene driven approach, whereby mutations 
are engineered into the mouse to study or confirm the function of the gene of 
interest.  Both forward and reverse genetics are tools that can advance 
understanding of disease processes.   
 
 In this thesis, I have used both forward and reverse genetics to identify 
genes involved in phosphoinositide metabolism that cause neurodegeneration in 
mouse and human.  Cloning of a spontaneous mouse mutant led to identification 
of a novel human disease, Charcot-Marie-Tooth disease type 4J (CMT4J).  To 
study CMT4J pathogenesis, a forward genetics approach was undertaken to
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produce a mouse model of CMT4J.  Further search for mouse mutants with 
similar phenotypes identified another mutant that affects the same pathway.  The 
work described in this thesis demonstrates the importance of mouse genetics to 
the study of human neurological disease. 
 
Charcot-Marie-Tooth disease 
Charcot-Marie-Tooth disease (CMT) is the most common type of inherited 
peripheral neuropathy, affecting 1 in 2500 people (Martyn and Hughes, 1997).   
CMT is a genetically heterogeneous group of disorders that affect the peripheral 
nerves.  CMT is characterized by muscular atrophy and weakness of the distal 
limbs.  This can also be accompanied by distal sensory loss, skeletal deformities 
and loss of tendon reflexes (Pareyson et al., 2006). 
 
The clinical presentation can be very similar between individuals with 
mutations in different genes.  More than 25 genes are implicated in CMT with 
diverse functions including, cytoskeletal elements, enzymes, transcription factors, 
and myelin structural proteins (Niemann et al., 2006).  Long distal nerves are first 
affected because dysfunction of any of these genes results in primary or 
secondary axonal degeneration that is highly length dependent.  The disease can 
affect either peripheral sensory nerves, motor nerves, or both (Niemann et al., 




CMT is subdivided based on inheritance and disease pattern (Table 1-1).  
CMT1 is autosomal dominant, primarily causing demyelination (Houlden and 
Reilly, 2006).  CMT2 is autosomal dominant, primarily causing degeneration of 
axons (Zuchner and Vance, 2006).  CMTX is X-linked, comprising up to 10% of 
CMT.  CMTX is associated with mutations in the GJB1/Cx32 gene (Kleopa and 
Scherer, 2006).  The majority of autosomal recessive forms fall into the CMT4 
group.  These are primarily demyelinating, though exceptions do exist.  CMT4 is 
rare and generally has an earlier onset and more severe disease than autosomal 
dominant forms (Dubourg et al., 2006).  Each form of CMT is further subdivided 
by the gene or locus responsible (i.e., CMT1A, CMT1B etc). 
 
Diagnosis is based on inheritance of the disease, as well as 
electrophysiological measurements of peripheral nerves from the affected 
patient.  Reduction in nerve conduction velocity (NCV) is a hallmark of a primary 
myelinopathy (CMT1).  A reduction of the nerve action potential with no change 
in the NCV is a sign of a primary axonopathy (CMT2).  A study resulting in a mix 
of both findings is classified as intermediate CMT (Pareyson et al., 2006). 
 
In some forms of CMT, the disease mechanism is straightforward.  For 
example, CMT1A is caused by duplications of (Lupski et al., 1991; Raeymaekers 
et al., 1991) or point mutations (Valentijn et al., 1992) in the PMP22 gene.  
PMP22 is a glycoprotein that is primarily expressed in myelinating Schwann 
cells.  It is a highly abundant protein, comprising a total of 2-5% of all PNS myelin 
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protein.  PMP22 is critically important for the formation and maintenance of 
compact myelin (Naef and Suter, 1998; Snipes et al., 1992).  Thus, it is not 
surprising that mutations in PMP22 cause demyelinating CMT.  However, for the 
majority of CMT subtypes, the pathophysiology is not as obvious. 
 
Genes involved in CMT can span the range of cellular functions.  Indeed, 
many CMT genes are ubiquitous “housekeeping” genes (Niemann et al., 2006).  
This poses a unique challenge to identifying the mechanism of disease, as CMT 
mainly affects peripheral nerves.  How dysfunction in ubiquitously expressed 
genes result in only a peripheral neuropathy and not a multi-organ disorder is a 
persistent question.  Both peripheral sensory neurons and spinal motor neurons 
have very long axons, up to one meter in some instances.  It has been proposed 
that the increased amount of trafficking required to maintain long axons may 
make these neurons highly sensitive to perturbations in ubiquitous, basic cellular 
pathways (Niemann et al., 2006).  Understanding this sensitivity will shed light on 
disease mechanism as well as basic peripheral nerve biology. 
 
Phosphoinositides 
The phosphoinositide pathway provides one such challenge. 
Phosphoinositides are a family of low abundance, signaling phospholipids that 
are generated from the phosphatidylinositol precursor.  Phosphatidylinositol is 
made up of two fatty acids and an inositol ring esterified to phosphatidic acid 
(Figure 1-1).  Phosphatidylinositol can be phosphorylated at the D3, D4, and D5 
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position of the inositol ring, resulting in seven naturally occurring 
phosphoinositides (Figure 1-2).  Phosphoinositides regulate a host of basic 
cellular functions including membrane and vesicle trafficking, cytoskeleton 
rearrangements, apoptosis, cell motility, and synaptic function (Di Paolo and De 
Camilli, 2006).   
 
 Phosphoinositides are localized in specific functional pools throughout the 
membrane system of the cell and are synthesized on the cytosolic face of 
membranes.  Phosphoinositide signaling occurs via recruitment of specific 
effector proteins.  These proteins often contain one or more binding domains that 
recognize a phosphoinositide.  Phosphoinositide binding domains include PH, 
ENTH/ANTH, FYVE, PX, Tubby and lysine/arginine-rich patches (Lemmon, 
2003).  Some domains have very strong affinity to one phosphoinositide, 
whereas other domains bind several different phosphoinositides dependent on 
the context of the interaction.   Binding of phosphoinositides not only localizes the 
proteins, but can also induce conformational and enzymatic changes (Di Paolo 
and De Camilli, 2006).  
 
Tight regulation of phosphoinositides is essential to proper signaling 
throughout the cell.  Phosphatases and kinases work in concert to interconvert 
and turnover the phosphate tags (Figure 1-2).  For example, PI(3)P is the 
predominant tag on early endosomes.  As the endosome progresses to late 
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endosome and lysosome, PI(3)P is converted to PI(3,5)P2 and becomes the 
predominant lipid signal (Figure 1-3) (Michell et al., 2006).   
 
CMT and phosphoinositides 
The cells involved in CMT, neurons and Schwann cells, are specialized in 
function.  Neurons with long axons, mainly innervating the distal portions of the 
body, are unique in several ways.  Neurons are post-mitotic and are sensitive to 
many insults because they are not replaced.  Neurons with long axons also have 
special challenges to maintain these complex structures.  Both retrograde and 
anterograde vesicle trafficking must be functional.  Anterograde trafficking allows 
transport of new membrane elements, proteins and neurotransmitters from the 
soma through the axon to the synapse.  Retrograde trafficking allows signaling 
proteins as well as cellular elements marked for recycling to be delivered to the 
soma for processing. 
 
Schwann cells also face unique challenges to proper function.  Schwann 
cells are the myelinating cells of the peripheral nervous system.  One Schwann 
cell myelinates multiple axons.  These cells produce large amounts of lipids and 
proteins to form and maintain the multi-laminar myelin sheaths on each axon.  





CMT subtypes differentially affect neurons and Schwann cells.  CMT1 
primarily affects Schwann cells and CMT2 primarily affects neuronal axons.  
However, neurons and Schwann cells do not function independently (Figure 1-4).  
Each must maintain its own integrity, but signaling is required between both cell 
types for either to function properly (Berti et al., 2006).  It is still unclear how 
exactly each cell type contributes to disease. 
 
Phosphoinositides are intimately involved in vesicle trafficking and 
cytoskeletal rearrangements, processes that are essential to the proper function 
of neurons and Schwann cells.  Dysfunction in ubiquitous phosphoinositide 
signaling genes have been implicated in several forms of CMT, including 
CMT4B1, CMT4B2, CMT4H, CMTDIB  (Suter, 2007), and in work described in 
this thesis, CMT4J (Table 1-2).   
 
CMT4B1 and CMT4B2 are clinically indistinguishable severe, early onset 
demyelinating peripheral neuropathies.  Both diseases are characterized by 
myelin outfoldings, abnormal myelin formations, and loss of myelinated axons.  
CMT4B1 and CMT4B2 are caused by mutations in MTMR2 (myotubularin-related 
protein 2) and MTMR13, respectively (Previtali et al., 2007).  MTMR2 and 
MTMR13 belong to a large family of proteins related to myotubularin.  MTMR2 is 
a phosphoinositide phosphatase that dephosphorylates PI(3)P and PI(3,5)P2 at 
the D3 position (Bolis et al., 2007).  The majority of CMT4B1 mutations result in 
loss of phosphatase activity (Previtali et al., 2007).  MTMR13 is a 
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pseudophosphatase with an inactive phosphatase domain.  MTMR13 forms a 
tetrameric complex with MTMR2 to increase the phosphatase activity of MTMR2 
(Berger et al., 2006). 
 
CMT4H is a recessive demyelinating neuropathy characterized by myelin 
outfoldings.  Mutations in Frabin/FGD4 are implicated in CMT4H (Delague et al., 
2007; Stendel et al., 2007b).  Frabin is a guanine-exchange factor (GEF) for the 
RhoGTPase Cdc42 (Umikawa et al., 1999).  Frabin contains a FYVE domain and 
two PH domains.  Both motifs are known phosphoinositide binding domains 
(Lemmon, 2003).  While MTMR2 and MTMR13 function to metabolize 
phosphoinositides, Frabin function requires the presence of phosphoinositide 
tags, suggesting the potential interplay between enzymes and effectors. 
 
CMTDIB is an autosomal dominant peripheral neuropathy, affecting both 
axons and Schwann cells.  Mutations in Dynamin 2 (DNM2) cause CMTDIB 
(Zuchner et al., 2005).  DNM2 also contains a PH domain.  Interestingly, all the 
CMTDIB mutations are clustered in the PH domain (McNiven, 2005; Zuchner et 
al., 2005), suggesting that disease is a direct effect of loss of interaction with 
phosphoinositides. 
 
Phosphoinositide-related CMT mouse models 
It is counterintuitive that changes in phosphoinositide signaling cause only 
a peripheral neuropathy and not a systemic disease.  On the one hand, 
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phosphoinositides are essential for all the processes described above.  Thus, it 
would be expected that neurons or Schwann cells would be compromised if the 
phosphoinositide pathways were abnormal.  On the other hand, 
phosphoinositides are essential to many basic cellular processes.  Perturbations 
of the phosphoinositide pathway would be expected to be incompatible with life 
due to their potential global effects.   
 
To better understand the exact pathophysiology of phosphoinositide 
dysfunction and CMT, it is important to study mouse models of these diseases.  
Mouse models are invaluable tools for disease research.  In order to fully 
understand the disease mechanism and develop viable therapies, the mouse 
model should closely mimic the human disease.  Technological advancements 
have allowed the mouse to become even more powerful.  Temporal conditional 
alleles allow the investigator to overcome biological difficulties such as embryonic 
lethality.  Spatial conditional alleles allow the investigator to answer questions 
involving cell autonomy as well as isolating an organ specific disease process. 
 
To date, only mouse models of CMT4B1 and CMT4B2 have been 
reported.  To model CMT4B1, two separate groups produced loss-of-function 
Mtmr2 mouse models.  The first mouse reported was a floxed allele of Mtmr2 
(Bolino et al., 2004).  Exon 4 was flanked by LoxP sites.  Floxed alleles allow for 
conditional deletion of the gene when crossed with a mouse carrying a CRE-
recombinase under the control of a temporal or spatial specific promoter.  The 
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floxed allele of Mtmr2 was crossed with a ubiquitous expressing Cre line.  This 
resulted in loss of Mtmr2 protein (Bolino et al., 2004).   
 
Mtmr2 null mice were viable and healthy, with no major neurological 
disease.  A minor gait abnormality was noted at 6 months of age.  Accompanying 
this was mildly reduced nerve conduction velocity and prolonged f-wave 
latencies, indications of sciatic nerve dysfunction.  These findings are consistent 
with peripheral neuropathy.  Little visible phenotype was observed before six 
months of age.  Mtmr2 null mice showed progressive changes in the myelin of 
peripheral nerves.  Myelin outfoldings were observed and the complexity of 
myelin structures increased with age.  Myelin outfoldings occurred prominently at 
the paranodal regions.  Both motor and sensory nerves were affected (Bolino et 
al., 2004).   Overall, the dysmyelinating phenotype of the Mtmr2 null mice 
resembled CMT4B1. 
 
A second Mtmr2 mouse model was also developed.  The nonsense 
mutation, E276X was knocked into the Mtmr2 locus (Bonneick et al., 2005).  
E276X was previously identified in a CMT4B1 family (Bolino et al., 2000).  While 
it was unclear whether the E276X protein was expressed in the mice (Bonneick 
et al., 2005), the putative truncated protein was shown to be nonfunctional and 
could not dephosphorylate PI(3)P and PI(3,5)P2, in vitro (Berger et al., 2002).  
Overall the pathology in the E276X mouse was similar to the Mtmr2 null mouse.  
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However, the E276X mouse showed no electrophysiological abnormalities up to 
16 months of age (Bonneick et al., 2005). 
 
It is important to note that Mtmr2 mouse models are not as severely 
affected as CMT4B1 patients.  CMT4B1 is a clinically homogenous, severe, 
childhood onset disease.  Mtmr2 mutant mice are marginally affected late in life 
and disease is best detected with careful histopathology.  It remains to be seen 
whether aged mice will show a more profound phenotype. 
 
While myelin outfoldings are a primary pathology in Mtmr2 mutant mice 
and CMT4B1 patients, it is unclear whether dysfunction resides in the axon, the 
Schwann cell, or both.  Mtmr2 is expressed in both neurons and Schwann cells.  
Myelin is produced by Schwann cells, but myelination requires communication 
between the axon and the Schwann cell.  To address this question, Bolis and 
colleagues (2005) made conditional Mtmr2 mutant mice.  The previously 
described floxed allele of Mtmr2 (Bolino et al., 2004) was deleted by a motor 
neuron specific Cre and a Schwann cell specific Cre.  This created mice with 
motor neurons that lacked Mtmr2 and mice with Schwann cells that lacked 
Mtmr2.  Mice lacking Mtmr2 in the motor neurons showed no signs of disease 
(Bolis et al., 2005).  There was no myelin pathology or functional evidence of any 
peripheral neuropathy.  However, conditional deletion of Mtmr2 in Schwann cells 
completely recapitulated the peripheral neuropathy observed in complete Mtmr2 
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null mice.  This data indicates that CMT4B1 pathology is a Schwann cell 
autonomous disease (Bolis et al., 2005).  
 
The role of Schwann cells is also demonstrated by the interaction between 
Mtmr2 and Dlg1, a scaffolding protein which links transmembrane proteins with 
the cytoskeleton.  In Schwann cells, Dlg1 is located at the paranodal junctions, 
where myelin outfoldings are often found (Bolino et al., 2004; Bolis et al., 2005).  
It remains to be seen what function Mtmr2 plays in neurons and if there are 
compensatory myotubularin-related proteins in neurons, but not Schwann cells. 
 
Two Mtmr13 deficient mice have also been reported (Robinson et al., 
2008; Tersar et al., 2007).  Not surprisingly, Mtmr13 mutant mice are similar to 
Mtmr2 mutant mice.  Both Mtmr13 mouse models were generated from gene-trap 
ES cell lines and were completely null.  Both models showed myelin outfoldings 
at the paranodes as well as other abnormal myelin structures.  Beginning at 6 
months, the myelin abnormalities progressively increased with age.  
Accompanying this pathology was also slowed nerve conduction velocity in both 
models, though one was more severe than the other (Robinson et al., 2008; 
Tersar et al., 2007).  One model demonstrated no functional deficits until 12 
months of age (Tersar et al., 2007).   
 
Mtmr13 mice are also much less severely affected than CMT4B2 patients.  
Mtmr2 and Mtmr13 double mutant mice were generated (Tersar et al., 2007).  
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The double mutant mice appeared to be no different from either single mutant 
mouse, consistent with a required Mtmr2 and Mtmr13 interaction. 
 
Mtmr2 and Mtmr13 mutant mice do not completely mimic CMT4B1 and 
CMT4B2.  While they do recapitulate key features such as myelin outfoldings, 
both mouse mutants are much less severe than the human diseases.  There are 
several reasons that can account for this.  First, the myotubularin gene family 
includes myotubularin and 13 related genes (Bolis et al., 2007).  Another 
myotubularin-related protein could be compensating for the loss of Mtmr2 and 
Mtmr13 in mouse, but not in human.  Second, the smaller size of the mouse may 
make the mouse peripheral nervous system less sensitive to perturbations.  
Because mice are smaller, axons extend a shorter distance and vesicle 
trafficking may be an easier task.  With shorter axons, Schwann cells produce 
much less myelin. 
 
Despite differences, these mouse models are valuable tools.  They have 
established the Schwann cell autonomous nature of CMT4B1.  This finding will 
help direct therapeutic interventions by focusing research on dysfunction of 
Schwann cells, rather than neurons.  These mouse models shed light on the 
molecular mechanism of disease when Mtmr2 and Mtmr13 are lost.  Levels of 
phosphoinositides have not been measured in these mice.  Further research is 
needed to identify which phosphoinositides are dysregulated due to mutations in 
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Mtmr2 and Mtmr13.  It is unknown if different phosphoinositides are dysregulated 
in neurons versus Schwann cells that cause a Schwann cell specific disease. 
 
To date, no mouse models of CMT4H (Frabin/FGD4) or CMTDIB (DNM2) 
have been reported.  It will be only a matter of time before these mice will be 
developed.  Mouse models of phosphoinositide-related CMT disease will 
continue to be a rich resource for the peripheral nerve community and will 
contribute to understanding of phosphoinositide function in the peripheral nerve. 
 
The data presented in this thesis demonstrates the importance of 
PI(3,5)P2 to health and disease.  Both reverse and forward mouse genetics were 
crucial in demonstrating this.  As known genes involved in phosphoinositide 
pathways are identified in disease, reverse genetics will provide a pathway to 
molecular understanding.  Forward genetics will identify new disease genes and 




Table 1-1. CMT subtypes and genetic loci that account for ~85% of CMT 
type inheritance major feature(s) genes/loci identified 
CMT1 AD Demyelinating Most common subtype 6 
AD Axonopathy 11 
CMT2 
AR Axonopathy Very rare 3 
DI CMT* AD Demyelinating and axonopathy 3 
CMT4 AR Demyelinating Early onset, severe 11 
CMTX X-linked Demyelinating and axonopathy 5** 
dHMN# AR, AD,          and X-linked 
Neuronopathy/axonopathy 
Motor neurons only 13 
 
*dominant intermediate CMT 
 
**Mutations in Cx32/GJB1 are the overwhelming majority with >220 mutations to 
date.  The four other loci are from one or two extended pedigrees. 
 





Figure 1-1. The structure of a phosphoinositide molecule.  The acyl fatty acid 
chain is inserted into the lipid bilayer and the inositol head group is exposed to 
the cytoplasm.  Positions D3, D4, and D5 can be phosphorylated in different 







Figure 1-2. Interconversion of phosphoinositides.  Seven different 
phosphoinositides can be produced.  Solid arrows indicate proven in vivo 
reactions.  Dotted arrows indicate established in vitro reactions.  PtdIns, 







Figure 1-3. PI3P and PI(3,5)P2 label endosomes and lysosomes.  PI3P labels 
endosomes.  As endosomes progress to late endosomes, mutivesicular bodies, 
and lysosomes, PI3P is increasingly converted to PI(3,5)P2.  PI(3,5)P2 is the 
predominant tag on late endosomes and lysosomes.  Adapted from (Volpicelli-







Figure 1-4. Schwann cells and axons.  a. A single Schwann cell axon unit.  
The Schwann cell ensheathes the axon in a thick layer of compact myelin.  b. 
High resolution image of the compact myelin surrounding an axon.  Modified from 




Table 1-2. CMT subtypes with mutations in phosphoinositide-related genes 
disease gene mutated phosphoinositide function 
CMT4B1 MTMR2 PI3P and PI(3,5)P2 3-phosphatase 
CMT4B2 MTMR13 Enhances function of MTMR2 
CMT4H Frabin/FGD4 Binds phosphoinositides via FYVE and PH domains 
CMT4J FIG4 PI(3,5)P2 5-phosphatase 







MUTATION OF FIG4 CAUSES NEURODEGENERATION IN THE PALE 




 Membrane-bound phosphoinositides are signaling molecules that play a 
key role in vesicle trafficking in eukaryotic cells (Di Paolo and De Camilli, 2006).  
Proteins that bind specific phosphoinositides mediate interactions between 
membrane-bounded compartments whose identity is partially encoded by 
cytoplasmic phospholipid tags.  Little is known about the localization and 
regulation of mammalian PI(3,5)P2, a quantitatively minor phosphoinositide that 
regulates membrane trafficking in the endosome-lysosome axis in yeast (Michell 
et al., 2006).  We describe a multi-organ disorder with neuronal degeneration in 
the CNS, peripheral neuronopathy, and diluted pigmentation, in the pale tremor 
mouse. Positional cloning identified an Etn2 retrotransposon insertion in intron 
18 of Fig4, the homolog of a yeast SAC-domain PI(3,5)P2 5-phosphatase located 
in the vacuolar membrane.  The abnormal concentration of PI(3,5)P2 in cultured 
fibroblasts from pale tremor mice demonstrates conserved biochemical function 
of mammalian FIG4. The cytoplasm of affected cells is filled with large LAMP2- 
immunoreactive vacuoles, consistent with dysfunction of the late endosome-
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lysosome. Neonatal neurodegeneration in sensory and autonomic ganglia is 
followed by loss of neurons from layers 4 and 5 of the cortex, deep cerebellar 
nuclei, and other localized brain regions. Sciatic nerve exhibits reduced numbers
of large diameter myelinated axons, slowed nerve conduction velocity, and 
reduced amplitude of compound muscle action potentials. We identified 
pathogenic mutations of human FIG4 (KIAA0274) on chromosome 6q21 in four 
unrelated patients with hereditary motor and sensory neuropathy. This novel form 
of autosomal recessive Charcot-Marie-Tooth disorder is designated CMT4J.    
 
Results and Discussion 
Mutant mice with severe tremor, abnormal gait, and diluted pigmentation 
were identified in our mouse colony on a mixed inbred strain background.  One 
breeding pair generated 8/30 affected progeny, consistent with inheritance of an 
autosomal recessive mutation designated pale tremor (plt).  At postnatal day 3 
(P3), affected homozygotes have diluted pigmentation and reduced size (Figure 
2-1a).  Intentional tremor develops during week 2, and abnormal limb postures 
are evident by week 3 (Figure 2-1b).  The impaired motor coordination, muscle 
weakness, and “swimming” gait of plt mice are demonstrated in the 
Supplementary video 
(http://www.nature.com/nature/journal/v448/n7149/suppinfo/nature05876.html).  
There is progressive loss of mobility, reduction in body weight and juvenile 




 To genetically map plt, a cross was carried out with strain CAST/Ei.  The 
recovery of affected F2 offspring was 9% (50/532), indicative of prenatal loss on 
this genetic background.  We genotyped 532 F2 animals with microsatellite and 
SNP markers to map plt to a 2 Mb interval of mouse chromosome 10 between 
D10Umi13 and D10Mit184 (Figure 2-1d).  There are 21 annotated genes in the 
nonrecombinant interval (www.ensembl.org; mouse build 35) and these were 
tested as candidates by sequencing RT-PCR products from brain RNA.  The plt 
transcript of A530089I17Rik lacks exons 19 through 23 from the 3’ end of the 
gene (Figure 2-2a).  Hybridization of a polyA+ Northern blot with a cDNA probe 
containing exons 8 to 15 identified a wildtype transcript of 3.3 kb that is not 
present in plt RNA (Figure 2-2c).  No abnormal transcripts were detected in the 
mutant, even when the exposure time was increased from 3 hrs to 63 hrs (not 
shown).  We were able to amplify exons 19-23 from genomic DNA, eliminating 
the possibility of a genomic deletion (Figure 2-2b).   
 
To identify the genomic mutation, we examined the structure of intron 18 
by PCR.  A wildtype product of 0.65 kb and a mutant product of 6.2 kb were 
amplified from the 3’ end of intron 18 (Figure 2-2d).  The sequence of the mutant 
product (GenBank DQ813648) contains a 5,547 bp insert with 99% sequence 
identity to mouse retrotransposon Etn2 (GenBank Y17106). The transposon is 
inserted 384 bp upstream of exon 19, in the same orientation as the gene, and 
flanked by a duplication of the  hexanucleotide CCCCTG (Figure 2-2g), 
characteristic of Etn2 insertions (Maksakova et al., 2006).  The mutant allele 
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can be detected by PCR with a primer in the LTR (Figure 2-2e).  Since the 
background strains do not contain the Etn2 element (data not shown), the plt 
mutation appears to be a result of transposon insertion. The data are consistent 
with abnormal splicing from exon 18 of FIG4 to one of the cryptic splice acceptor 
sites in the Etn2 element (Maksakova et al., 2006), generating a transcript of 
very low abundance that is detected by RT-PCR but is below the sensitivity of the 
polyA+ Northern blot.       
 
RT-PCR of tissues from wildtype mice demonstrated widespread 
expression (Figure 2-2f), consistent with public EST and microarray databases.  
In situ hybridization data demonstrates distribution of the transcript throughout 
the brain (www.brainatlas.org/aba/ and unpublished).  The human ortholog, 
KIAA0274, is located on human chromosome 6q21.  The mutated protein is most 
closely related to the yeast SAC-domain phosphatase Fig4, with overall amino 
acid sequence identity of 35% and similarity of 66%. The SAC domain with the 
active site motif CX5R(S/T) is characteristic of phosphatases with specificity for 
phosphoprotein or phospholipid substrates (Hughes et al., 2000) and exhibits 
44% sequence identity (191/435 aa) (Figure 2-3a).   The four other mammalian 
genes with SAC domains (synaptojanin 1, synaptojanin 2, INPP5F and SAC1) 
differ from Fig4 at other domains (Hughes et al., 2000), indicating that mouse 
A530089I17Rik and human KIAA0274 are homologs of yeast Fig4.   
 
 Yeast Fig4p is localized to the vacuolar membrane and is required for both 
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generation and turnover of PI(3,5)P2 (Duex et al., 2006b).  Fig4p exhibits lipid 
phosphatase activity towards  the 5-phosphate residue of PI(3,5)P2 (Rudge et al., 
2004), and also appears to activate the Fab1/PIKfyve kinase that synthesizes 
PI(3,5)P2 from PI3P, possibly by dephosphorylating the kinase or one of its 
regulators (Duex et al., 2006b).  As a result, deletion of yeast Fig4 reduces rather 
than increases the intracellular concentration of PI(3,5)P2 (Duex et al., 2006a), 
leading to defects in vacuole fission, formation of enlarged vacuoles, and impaired 
retrograde traffic to the late endosome (Bonangelino et al., 2002; Gary et al., 
2002; Michell et al., 2006).  Knock-down of mammalian Fab1/PIKfyve kinase 
causes a similar defect in retrograde endosome traffic and enlarged vacuoles 
(Rutherford et al., 2006).  
 
Analysis of phosphoinositides from cultured fibroblasts of plt mice 
demonstrated a three-fold reduction in PI(3,5)P2 (p=0.04), with no change in 3 
other phosphoinositides (Figure 2-3b).  Enlarged cytoplasmic vacuoles 
accumulate in 40% of cultured fibroblasts from plt mice (174/435) compared with 
5% of wildtype cells (22/403) (Figure 2-3c).  These vacuoles stain positively for 
the lysosomal membrane protein LAMP2 (Figure 2-3d), indicating that they 
represent late-stage endosomes.  The altered levels of PI(3,5)P2 demonstrate a 
conserved enzymatic function of FIG4 from yeast to mammals, while the 
enlarged vacuoles demonstrate a conserved cellular role in regulation of the size 




In vivo loss of FIG4 results in a striking pattern of selective 
neurodegeneration.  Extensive loss of neurons from sensory and autonomic 
ganglia is evident during the neonatal period (Figure 2-4a-d). The presence of 
neurons with enlarged cytoplasmic vacuoles suggests that vacuole accumulation 
may precede cell loss (Figure 2-4 inserts).  Spinal motor neurons exhibit normal 
morphology at 3 weeks (Figure 2-4e-f) but contain vacuoles at 6 weeks of age 
(Figure 2-4g-h). 
 
Peripheral nerves are also affected.  Cross-sections of sciatic nerve reveal 
substantial reduction in the number of large diameter myelinated axons in the 
mutant (Figure 2-5a-b). Nerve conduction velocity and amplitude of compound 
muscle action potentials are reduced (Figure 2-5c-d), consistent with the axonal 
loss visible in the semithin sections of the sciatic nerve and the pathological 
abnormalities in the motor neurons.  There was no response when recording 
from tail sensory fibers, consistent with the severe loss of sensory neurons from 
the DRG.   
 
 In the brain, neuronal loss in the thalamus, pons, medulla and deep 
cerebellar nuclei is visible at 1 week of age (not shown).  By 3 weeks of age 
there is additional loss of neurons from cortical layers 4 and 5, the deep layers of 
the superior and inferior colliculus and the olfactory bulb (Figure 2-6a). Some 
neuronal cell bodies contain enlarged vacuoles (Figure 2-6b); these vacuoles are 
not stained by Oil Red O (for lipid) or PAS (for carbohydrate) (not shown).  
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Hippocampus, cerebellar cortex, and cerebral cortex layers 1, 2, 3 and 6 remain 
relatively unaffected throughout the course of the disease, although under culture 
conditions hippocampal neurons become vacuolated (not shown).  The abnormal 
gait and motor coordination in the plt mutant may be accounted for by abnormal 
proprioception due to degeneration of DRG neurons, in combination with 
degeneration of neurons from brain regions directly involved in motor control 
(layer 5 of the cortex, thalamus and deep cerebellar nuclei). 
 
Abnormalities are visible in skin and spleen.  Pigment-containing hair 
follicles are greatly reduced in number and the few pigmented hairs contain 
clumped melanosomes (Figure 2-7a-d), similar to mouse mutants with defects in 
lysosome-melanosome biogenesis (Marks and Seabra, 2001).  There is 
extensive cell loss in the spleen (Figure 2-7e-f).  White blood cell profiles are 
normal, and liver, kidney, and testis appear normal by light microscopy.    
 
The clinical and pathological features of peripheral neuropathy in pale 
tremor mice resemble some types of Charcot-Marie-Tooth disease (Schroder, 
2006; Szigeti et al., 2006).  We tested FIG4 as a candidate gene by screening 95 
individuals diagnosed with CMT but lacking mutations in known genes (Szigeti et 
al., 2006).  The 23 coding exons of FIG4 were amplified from genomic DNA, 
screened by heteroduplex analysis and sequenced.  Patient BAB 1079 has a 
severe, early onset disorder.  We identified the protein truncation mutation 
F98fsX102 in exon 4 and the missense mutation I41T in exon 2 of FIG4 (Figure 
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2-8a).  F98fsX102 truncates the protein within the SAC domain and is likely to be 
a loss of function allele.  Pedigree analysis demonstrated autosomal recessive 
inheritance.  Each mutation was inherited from a heterozygous parent (Figure 2-
8b).  Two heterozygous carriers of F98fsX102 are unaffected, indicating that 
FIG4 is not haploinsufficient.  Heterozygous plt/+ mice aged to 18 months are 
also unaffected. 
 
Patient BAB1372 was also found to be a compound heterozygote with a 
nonsense mutation R183X in exon 6 together with I41T (Figure 2-8a). R183X 
was inherited from the patients’ father (Figure 2-8b).  The mother is an obligate 
carrier of I41T, and the affected sibling inherited both mutations (Figure 2-8b). 
The siblings have severe disease: BAB1372 is functionally quadriplegic and 
BAB1373 is wheelchair-bound while retaining normal use of his arms.  Both have 
slow nerve conduction velocities.  A sural nerve biopsy for BAB1373 
demonstrated profound axonal loss, thinly myelinated nerve fibers, and evidence 
of de- and remyelination.   
 
Two additional patients, BAB1161 and BAB1369, carry unique truncation 
mutations together with I41T (Figure 2-8a).  Both patients developed disease by  
5 years of age and demonstrate reduced nerve conduction velocity  (2 to 7 m/s, 
compared with normal values of 40-50 m/s).  One patient had motor 




It is remarkable that four unrelated Caucasian patients carry the same 
missense mutation.  No additional coding or splice site variants were detected in 
these patients when all 23 exons of FIG4 were sequenced.  Isoleucine 41 is 
located upstream of the SAC phosphatase domain and is evolutionarily invariant 
in FIG4 from yeast, invertebrates and vertebrates (Figure 2-8c-d).  We did not 
identify carriers of this variant by sequencing exon 2 from 295 neurologically 
normal Caucasian controls  The observed allele frequencies were 0/590 in 
controls and 4/190 in CMT patients (p=0.003). The four patients carry I41T on the 
same 15 kb haplotype, defined by SNPs rs3799845 (G), rs2025249 (C) and 
rs7764711 (G) (haplotype frequency 0.29), consistent with inheritance of a 
common ancestral mutant allele (Figure 2-9).  The evidence suggests that I41T is 
a partial loss of function allele with population frequency below 0.005 that is 
pathogenic only in combination with a null allele of FIG4.  
 
To assess the functional effect of the I41T allele, we tested the 
corresponding mutation (I59T) in yeast.  Wildtype and mutant cDNAs were 
transformed into Fig4 null yeast strain lacking functional Fig4 (Duex et al., 
2006a).  Transformation with vector only did not correct the enlarged vacuoles in 
Fig4 null cells which reflect the slightly reduced levels of PI(3,5)P2 that result 
from the absence of Fig4 (Duex et al., 2006a) (Figure 2-10a).  Vacuolar 
enlargement was corrected to a comparable extent by WT and mutant Fig4, 
indicating that under basal conditions cells expressing Fig4I59T produce normal 
levels of PI(3,5)P2 (Figure 2-10a). The ability of the mutant to activate 
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Fab4/PIKfyve kinase was tested by treatment with hyperosmotic shock as 
previously described (Duex et al., 2006a; Duex et al., 2006b).  In cells expressing 
wildtype Fig4, hyperosmotic shock produces a transient 10-fold increase in 
intracellular PI(3,5)P2 concentration due to activation of Fab1/PIKfyve kinase 
(Figure 2-10b). In cells expressing the mutant, a partial increase of 4-fold was 
observed, demonstrating impaired activation of Fab1/PIKfyve kinase.  It is not 
clear whether the phosphatase activity of the mutant is also impaired, due to the 
low levels of PI(3,5)P2. 
 
The data presented here demonstrate that mutation of FIG4 is responsible 
for peripheral neuronopathy in human patients.  We propose the designation 
CMT4J for this disorder, based on the recessive inheritance pattern.  
Phosphoinositide signaling has previously been implicated in Charcot Marie 
Tooth type 4B1, 4B2 and 4H (Begley et al., 2006; Bolino et al., 2004; Bolino et 
al., 2000; Bonneick et al., 2005; Senderek et al., 2003; Stendel et al., 2007a).  
Other genes that function in vesicle trafficking, such as Rab7 and dynamin 2 in 
human (Verhoeven et al., 2003; Zuchner et al., 2005) and Vps54 in mouse 
(Schmitt-John et al., 2005), are associated with inherited neuropathies. 
 
The plt mutant provides the first evidence regarding the functional role of 
mammalian Fig4.   The results demonstrate a conserved biochemical function in 
metabolism of PI(3,5)P2, a conserved cellular role in regulation of endosomal 
vesicles, and an unexpected role in neuronal survival. The molecular basis for 
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the differential sensitivity of neuronal subtypes to loss of this widely expressed 
gene is unclear. The key role of PI(3,5)P2 in differential neuronal sensitivity is 
supported by the observation of a very similar pattern of neuronal loss in a 
mouse mutant of Vac14 (Zhang et al., 2007).  Vac14 is the homolog of a yeast 
protein that complexes with and activates Fig4p (Duex et al., 2006a).  
Mammalian Vac14 is located in synaptic microsomal membrane fractions and 
interacts with neuronal nitric oxide synthase (Lemaire and McPherson, 2006).  
Neuronal dependence on FIG4 may be related to the role of endosomal vesicles 
in delivering membrane components to dendritic spines during long-term 
potentiation (Park et al., 2006).  The pale tremor mouse will be useful for 
investigation of PI(3,5)P2 signaling in neurons and as a model for CMT and 






Figure 2-1. Phenotypes and genetic mapping of pale tremor mice.  a. Diluted 
pigmentation at postnatal day 3 (P3).   b. Abnormal limb postures at P24.   c. 
Juvenile lethality of F2 mice from the CAST/Ei cross (n= 50).  d. Genetic 
mapping of plt on mouse chromosome 10. The haplotypes of 3 recombinant 
chromosomes and 1,061 nonrecombinant chromosomes are indicated; solid 
symbols represent alleles from inbred strains; open symbols represent CAST 
alleles. The 2 Mb nonrecombinant interval of mouse chromosome 10 between 






Figure 2-2. Fig4 is mutated in the pale tremor mice.  a. RT-PCR of the Fig4 
transcript from wildtype tissues with primers in the indicated exons.   b. PCR of 
genomic DNA using primers flanking exons 19 through 23.  c. Northern blot 
containing 3 ug of brain polyA+ RNA, isolated at P7 prior to extensive 
neurodegeneration, hybridized with 1 kb Fig4 cDNA probe (exons 8 to 15).  RNA 
integrity and equal loading of samples indicated by the intensity of minor bands 
(9-10 kb).  d. Long-range PCR of genomic DNA using the indicated primers in 
intron 18 and exon 19.  e. Three-primer genotyping assay for the Fig4plt allele 
with Etn2 insertion produces a 646 bp wildtype product and a 245 bp plt 
fragment; MW markers at left (kb).  f. RT-PCR of the Fig4 transcript from wildtype 
tissues; primers located in exon 8 and exon 15.  g. Etn2 retrotransposon in 






Figure 2-3. Mouse Fig4 has conserved function.  a. Protein domains of yeast 
Fig4p and mammalian homologs. See text for description of the SAC 
phosphatase domain.  b. Altered abundance of the phosphoinositide PI(3,5)P2 in 
cultured fibroblasts from mutant mice.  mean ± SD (n=6).  c. Mutant fibroblasts 
are filled with vacuoles.  d. Membranes of large cytoplasmic vesicles stain with 





Figure 2-4. Neuropathology in pale tremor mice.  a-b. trigeminal ganglia, c-d. 
dorsal root ganglia from lumbar region.  Insets reveal cytoplasmic vacuoles.  
Superior cervical ganglia have a similar appearance.  e-h. Spinal cord ventral 
horn.  arrow, motor neuron cell body.  Scale bars: 25 microns for panels a-g, 12.5 





Figure 2-5. Pathological abnormalities in peripheral nerves.  a-b. Semi-thin 
sections of sciatic nerve prepared as described(Li et al., 2006) demonstrating 
reduced density of large diameter myelinated axons in plt mutant.  Scale bars: 10 
microns.  c-d. Reduced sciatic nerve conduction velocity (mutant = 11.0 ± 3.4 
m/sec, wildtype = 21.5 ± 6.3) and reduced amplitude of compound muscle action 






Figure 2-6. Brain degeneration in pale tremor mice.  a. Sagittal section of the 
brain of a pale tremor mouse.  V, enlarged ventricle.  b. Neuronal cell bodies 






Figure 2-7. Pigment and spleen abnormalities in pale tremor mice.  a-b. Skin 
wholemounts from P10 mice demonstrating pigment-containing hair follicles. 
Original magnification: 8.5X.  c-d. Melanosome clumping in mutant hair shafts 
(arrows). Original magnification: 10X.  plt (e) and wt (f) spleens from 3 week old 






Figure 2-8. Mutations of FIG4 in patients with Charcot-Marie-Tooth disease.   
a. Sequencing chromatographs for four unrelated patients with Charcot-Marie-
Tooth disease.  b. Inheritance of mutant alleles in two pedigrees.   BAB1079 is a 
compound heterozygote for protein truncation mutation F98fsX102 and missense 
mutation I41T.  BAB1372 and BAB1373 are compound heterozygotes for nonsense 
mutation R183X and missense mutation I41T.  c. Residue isoleucine 41 is 
evolutionarily invariant in FIG4 from vertebrates, invertebrates and yeast.  d. 
Location of CMT mutations in the FIG4 protein.  Solid circles, protein truncation 






Figure 2-9. Haplotypes of CMT patients with mutations in FIG4. 
a. Genotypes. Seven SNPs from the HapMap database, and the Ile41Thr 
mutation (c.122T>C) were genotyped for patients and family members.  b. 
Haplotypes. The five SNPs shown in black were informative in the two available 
pedigrees and permitted reconstruction of the haplotypes. The Ile41Thr 
(c.122T>C) allele is carried by the same haplotype in all four patients. The 
Ile41Thr allele has a calculated LD coefficient D' equal to 1 for rs3799845, 






Figure 2-10. Yeast Fig4Ile>Thr is defective in activation of kinase 
Fab1/PIKfyve.  The fig4 null yeast strain lacking endogenous Fig4p (Duex et al., 
2006a; Duex et al., 2006b) was transformed with empty vector (vector), wildtype 
myc-Fig4 (WT), or myc-Fig4 containing I59T corresponding to human I41T 
(mutant).  a. Yeast were labeled with FM4-64 to assess vacuole volume, an 
indicator of basal levels of PI(3,5)P2.  b. Time course of PI(3,5)P2 levels after 
hyperosmotic shock reflects activation of Fab1 kinase. Compared with wildtype, 
the mutant protein exhibits impaired activation at 10 min (p=0.004) (mean ± SD, 
n = 3).   
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Materials and Methods 
Animals 
The plt mutation arose on a mixed background derived from inbred strains  
129/Ola, C57BL/6J, C3H, and SJL (Adamska et al., 2005).  For genetic mapping, 
plt/+ heterozygotes were crossed with strain CAST/Ei (Jackson Laboratory, Bar 
Harbor, ME).  This research was approved by the University of Michigan 
Committee on Use and Care of Animals.  Animals were housed and cared for in 
accordance with NIH guidelines. 
 
Genotyping and Markers    
Genotyping was carried out using microsatellite markers from public 
databases as well as novel microsatellite markers designed from mouse genomic 
sequence (www.ensemble.org).  D10Umi13 was amplified with the forward 
primer 5’-CCACC ACATC AACAG GCTCA CAGG and reverse primer 5’-
AATGCAACCG TGACA CAAGT ACAC. PCR was carried out with the PCR core 
kit (Qiagen).  PCR products were separated on 6% acrylamide gels and stained 
with ethidium bromide. The plt mutation is genotyped by PCR with a forward 
primer in intron 18 (5’ CGTAT GAATT GAGTA GTTTT GATG) and two reverse 
primers, one in the proximal LTR of the inserted Etn2 element (5’ GCTGG 
GGGAG GGGAG ACTAC ACAG) and one in exon 19 (5’ ATGGA CTTGG 






Total RNA was isolated from brain of P7 mice, prior to extensive 
neurodegeneration.  cDNA was synthesized using the First Strand cDNA 
Synthesis Kit (Invitrogen Corp.).  RT-PCR was carried out with the PCR Core Kit 
(Qiagen).   Long range PCR was performed with the Expand Long Template 
PCR System (Roche).  
 
Northern blot 
The Northern blot with 3 ug of polyA+ RNA was prepared as previously 
described (Kohrman et al., 1996).  The hybridization probe, a 1 kb RT-PCR 




Tissues were sectioned and stained at HistoServ (Germantown, MD).  
Fast blue/eosin staining was carried out in the Department of Pathology, 
University of Michigan.  Light microscopy was performed on an Olympus BX-51 
microscope and DP50 camera.  Sciatic and femoral nerves were sectioned and 
stained with osmium for electron microscopy as previously described (Li et al., 
2006).  Skin whole mounts were prepared from P10 mice with the guidance of 
Dr. Andrzej Dlugosz, Department of Dermatology, University of Michigan.  The 
commercial depilatory Nair was applied to the dorsal surface for five minutes 
followed by washing with warm water to remove hair.  The skin was dissected 
 
 44
and superficial fascia removed.  Follicles were visualized on a standard 
dissecting microscope with transmitted light. 
 
Neurophysiology 
Nerve conduction velocities were recorded from affected pale tremor mice 
and littermate controls.  Mice were anesthetized with ketamine/zylazine and 
placed under a heating lamp to maintain body temperature at 32oC.  Recordings 
were obtained using a Nicolet VikingQuest portable system and Nicolet 
disposable EEG needles.  Tail sensory responses were obtained by stimulating 
proximally over a 3 cm region.  Sciatic nerve motor velocities were obtained by 
stimulating distally at the sciatic notch and proximally at the knee.   
 
Cell culture and immunoflouresence 
Primary fibroblasts were cultured from mouse tail biopsies treated with 
collagenase.  Cells were plated in Dulbecco’s modified Eagle medium (DMEM) 
with fetal bovine serum (FBS) and maintained at 37o C with 5% CO2 for up to 3 
passages.  For immunoflouresence, 100,000 cells were seeded on polylysine-
coated cover slips in 35 mm dishes.  We thank Dr. Thomas August and the 
Developmental Studies Hybridoma Bank (University of Iowa, IA) for mAbs LAMP-
2, developed under the auspices of the NICHD and maintained by the 
Department of Biological Sciences, University of Iowa, Iowa City, IA 52242.  For 
labeling with antibody, cells were fixed with ice cold methanol at -20o C for 5 min. 
and blocked with 2% goat serum.  Antibodies were applied for 1 hour in PBS with 
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2% serum at room temperature and detected with Alexa fluor 488 donkey anti-
rabbit or Alexa fluor 594 goat anti-rat (Molecular Probes).  Cells were visualized 
on a DeltaVision Deconvolution microscope system (Applied Precision).  
 
Hippocampal neurons were cultured with glial conditioned media.  
Neurons were visualized with a Nikon TE2000 microscope.    
 
Phosphoinositide assays 
Fibroblast phosphoinositides were labeled with myo-[2-3H] inositol, 
extracted, and quantitated by HPLC.  Mouse fibroblasts from the first passage 
were grown in 100 mm dishes to 60%-70% confluency. The culture was rinsed 
with PBS and starved for 12 hours in inositol-free DMEM (Tissue culture support 
center, Washington University, MO) supplemented with 5 ug/ml transferrin, 5 
ug/ml insulin and 10% dialyzed fetal bovine serum. The medium was replaced 
with labeling medium (inositol-free DMEM containing 5 ug/ml transferrin, 20 mM 
Hepes, and 50 uCi myo-[2-3H] inositol (GE Healthcare, Piscatway, NJ)). After 24 
hours, the culture was treated with 0.6 ml of 4.5% (v/v) perchloric acid for 15 min, 
scraped off the plate, and spun down at 12,000xg for 10 min at 4°C. The pellet 
was washed with 0.1 M EDTA once and resuspended in 50 ul deionized water. 
To deacylate the lipids, samples were transferred to a glass vial, mixed with 1 ml 
methanol/40% methylamine/n-butanol (4:4:1, v/v) and incubated at 55°C for 1 
hour. The resulting samples were vacuum dried, resuspended in 0.3 ml water 
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and extracted twice with an equal volume of butanol/ethyl ether/formate (20:4:1, 
v/v). The aqueous phase was vacuum dried and resuspended in 20 ul water.  
 
For separation of all isoforms of the glycerophosphoinositides by HPLC, 
two different elution gradients were used at 1 ml/min flow rate. (pump A: H2O; 
pump B: 1M (NH4)2HPO4, pH3.8). Gradient 1: 0% B for 5 min; 0 – 2% B over 15 
min; 2% B for 80 min; 2 -12% B over 20 min; 12% B for 20 min; 12 - 80% B over 
40 min; 80% B for 20 min; 80 – 0% B over 5 min. To separate GroPIns(3,4)P2 
from GroPIns(3,5)P2, a longer gradient was used: 0% B for 5 min; 0 – 2% B over 
15 min; 2% B for 80 min; 2 -10% B over 20 min; 10% B for 65 min; 10 - 80% B 
over 40 min; 80% B for 20 min; 80 – 0% B over 5 min, The positions of 
GroPIns(3)P, GroPIns(3,5)P2, GroPIns(3,4)P2 and GroPIns(3,4,5)3 were 
determined by 32P labeled standards received as gifts from Dr. Lucia Rameh 
(Boston Biomedical Research Institute, MA).  The positions of GroPIns(4)P and 
GroPIns(4,5)P2 were confirmed with yeast glycerophosphoinositide extracts.  
 
Human mutation detection  
The cohort of unrelated patients with CMT was previously described 
(Szigeti et al., 2006).  The clinical diagnosis was based on clinical examination, 
electrophysiological studies, and in a few cases, nerve biopsy.  All patients 
received appropriate counseling and gave informed consent approved by the 
institutional review board.  For the initial screen of FIG4, each coding exon was 
amplified and examined by heteroduplex analysis as previously described 
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(Escayg et al., 2000).  The patient mutations were identified by sequencing 
products exhibiting abnormal mobility.  Subsequently, the 23 exons of FIG4 were 
completely sequenced from the four individuals carrying variants.   Genomic DNA 
from neurological normal control individuals was obtained from the Coriell 
Institute (panels NDPT006 and NDPT009, 96 samples each) and from a 
collection of 111 subjects older than 60 years of age without personal or family 
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The pale tremor mouse is a null allele of Fig4 (referred to as Fig4-/-).  pale 
tremor displays severe peripheral neuropathy, neurodegeneration in the CNS 
and pale coat color.  Study of pale tremor led to identification of CMT4J patients 
with mutations in FIG4 (Chow et al., 2007).  All four CMT4J families have one 
protein truncating, null mutation and the missense mutation I41T (genotype 
FIG4I41T/-).   
 
In yeast, the I41T allele has partial function and results in reduced levels 
of PI(3,5)P2 (Chow et al., 2007).  Yeast carrying I41T also have an enlarged 
vacuole phenotype similar to Fig4 null cells (Chow CY, unpublished results).  
Fig4-/- mice die by six weeks of age.  CMT4J patients are less severely affected 
and one family has adult onset disease.  CMT4J patients do not have pigment 
abnormalities or develop CNS dysfunction (Chow et al., 2007).  The phenotypic 
difference between Fig4-/- mice and CMT4J patients suggests that I41T may be a 
partially functioning allele.   
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To test this hypothesis, I sought to make a transgenic mouse model of 
CMT4J.  I hypothesized that the CMT4J mouse model would closely mimic 
CMT4J disease with severe peripheral neuropathy without any CNS involvement 
or pigment abnormalities. 
 
Results 
Generation of I41T transgenic mice 
Fig4 is a ubiquitous protein (Chow et al., 2007), thus I sought to match the 
expression of the transgene to endogenous Fig4.  The I41T transgene consists 
of the mouse Fig4 cDNA cloned downstream of a CMV enhancer and -actin 
promoter (Figure 3-1).  The CMV enhancer and -actin promoter provide broad 
expression (Buchner et al., 2003; Niwa et al., 1991).  However, expression of 
transgenes can be highly insertion site dependent.  Site directed mutagenesis 
was performed to insert the I41T mutation into the mouse cDNA.  The I41T 
transgene was injected by the University of Michigan Transgenic Animal Model 
Core.  Genotyping of the transgene was performed with a forward primer in the 
-actin promoter and a reverse primer in the cDNA (Figure 3-1).  This amplifies 
the transgene and not the endogenous locus.  Sixty nine potential founders were 
born.  Eleven transgenic founders were identified by PCR genotyping.  Five 
transgenic founders transmitted to the next generation.  Three lines, Tg721, 




RT-PCR was performed on brain cDNA to evaluate expression of Fig4.  
To distinguish transgene expression from endogenous expression, analysis was 
conducted on Fig4-/-, Tg+ mice (see below).   Fig4-/- mice do not express 
endogenous Fig4 mRNA (Figure 3-2) (Chow et al., 2007).  Fig4-/-, Tg+ animals 
only express Fig4 from the transgene.  Tg716 Fig4 transcript levels were close to 
those of the endogenous gene, while Tg721 and Tg705 are expressed at 
approximately twice the level of endogenous Fig4 (Figure 3-2).   
 
Due to variability in the phenotype of the Tg716 line, it was discarded and 
not included in the study.  Fig4-/-, Tg716+ mice exhibited two different 
phenotypes.  50% of the Fig4-/-, Tg716+ survived past 4 months of age and 
appeared to be unaffected.  However, the other half of the Fig4-/-, Tg716+ mice 
died by five weeks age and were identical in phenotype to the original Fig4-/- 
mice.  This data is consistent with two independent transgene insertions where 
one site is not being expressed and does not recue the null phenotype. 
 
Tg721 and Tg705 transmitted in Mendelian ratios consistent with one 
insertion site (Table 3-1).  Transgene positive mice from both lines are 
indistinguishable from wildtype littermates at all ages, indicating no detectable 






The I41T transgene rescues the Fig4-/- lethal phenotype 
Tg721 and Tg705 were both bred onto the Fig4-/- background (Figure 3-3).  
Because no endogenous FIG4 protein is expressed (Chow et al., 2007), the  
Fig4-/-, Tg+ mice are similar to CMT4J patients expressing only the I41T protein.  
Results are similar from both transgene lines and will not be differentiated.    
Fig4-/-, Tg+ mice develop and grow similar to wildtype littermates (Figure 3-4), and 
have normal neuromuscular function as measured by the hanging wire test 
(Figure 3-5).  Fig4-/-, Tg- mice quickly develop a movement disorder and die by 
six weeks of age (Figure 3-6).  At seven months of age, there is still no sign of 
neurological disorder or lethality in the Fig4-/-, Tg+ mice (Figure 3-4, 3-5, and 3-6).  
One mouse from the Tg721 line died at 4 months of age (1/12) and appeared to 
have severe hydrocephalus, but no other mice have become sick. 
 
While the neurological and early lethality phenotypes are rescued by the 
I41T transgene, all Fig4-/-, Tg+ mice have diluted coat color similar to Fig4-/-, Tg- 
mice (Figure 3-7).  Fig4-/-, Tg+ mice are easily identifiable at 3 days of age, as 
they are lighter in pigmentation than wildtype littermates.  Fig4-/-, Tg+ mice 







The Fig4 variant R905C in mouse strain WSB/EiJ and a human patient with 
CMT. 
 In the course of the CMT screen for FIG4 mutations (Chapter II), I 
identified a novel missense variant in patient BAB1591.  The variant, c2713 C>T, 
is in exon 23 and results in the amino acid substitution R905C, three residues 
from the end of the protein (Figure 3-8a,b).  Arginine 905 is evolutionarily 
invariant in all vertebrates (Figure 3-8c), but the carboxy terminus of FIG4 is not 
conserved between human and yeast.  Patient BAB1591 has autosomal 
recessive CMT with spinocerebellar ataxia (CMT+SCA).  Sequencing of all FIG4 
coding exons from patient BAB1591 did not identify a second mutation.  R905C 
was not identified in 363 neurologically normal controls. 
 
To find nonsynonymous variants in mouse, I searched the NCBI Entrez 
SNP database (http://www.ncbi.nlm.nih.gov/sites/entrez?db=snp ).  Mouse SNPs 
identified in the Perlegen resequencing project have been deposited in this 
database (Frazer et al., 2004).   The mouse strain WSB/EiJ was one of the 
resequenced mouse strains and carries the same nonsynonymous SNP, R905C, 
in Fig4.  WSB/EiJ genomic DNA was ordered from the Jackson Lab and 
sequenced to confirm the presence of R905C (Figure 3-9a).  WSB/EiJ mice have 
a very subtle pale agouti coat color (aw/ aw) and no obvious neurological deficits.  
I imported these mice and performed a complementation test with the Fig4 null 
allele (Figure 3-9b).  Compound heterozygous mice Fig4R905C/- do not have a 
neurological phenotype.  The original pale coat is subtle and it is unclear if 
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compound heterozygous mice have the same subtle pale agouti coat color.  
These mice will be aged and monitored for neurological phenotypes.  The 
Fig4R905C allele is currently being bred onto a black coat color (a/a) (Figure 3-9c), 
because this might make the pale coat phenotype more evident than on aw/ aw.  
Fibroblasts have also been cultured from Fig4R905C/- mice.  The fibroblasts have a 
similar fraction of vacuolated cells compared to control fibroblasts (Fig4R905C/- 
cells, 24% vacuolated; Fig4R905C/+ cells, 26% vacuolated). 
 
Discussion 
 Charcot-Marie-Tooth disease type 4J is caused by mutations in FIG4.  
Here I report a transgenic mouse that may be a new model of CMT4J (CMT4J 
mice).  The I41T transgene rescues early lethality and neurological disease 
observed in the Fig4-/- mouse. Despite having normal growth and neurological 
function, CMT4J mice have a pale coat color.  The I41T transgene fails to rescue 
the pigment defect.  The data presented in this report indicates that the I41T 
allele retains enough activity for nervous system function and survival.  
 
It is evident at P3 that the CMT4J mice have a dilute coat color similar to 
the original Fig4-/- mice.  It is unknown why loss of FIG4 function results in diluted 
pigment.  Melanosomes are specialized organelles synthesized by melanocytes, 
pigment cells in the skin (Marks, 2008).  Melanosomes originate from late 
endosomes (Marks, 2008; Raposo and Marks, 2007).  Endosome and lysosome 
trafficking is abnormal is Fig4-/- fibroblast and neurons (Chow et al., 2007).  
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Perhaps a similar defect in endosome/lysosome trafficking is present in 
melanocytes, preventing synthesis and delivery of pigment to the hair. 
 
Careful analysis of melanocytes and pigment biogenesis in CMT4J mice 
and Fig4-/- mice is warranted.  I have not analyzed I41T transgene expression in 
melanocytes in the CMT4J mice.  If the transgene is not expressed, then the 
pigment phenotype is simply identical to Fig4-/- and not being rescued because 
I41T is not expressed in the appropriate cell type.  Pale coat color was observed 
in three independent lines.  It is likely that I41T is a partial functioning allele and 
does not retain the necessary function for the production of pigment in mice.  
Studies involving the role of Fig4 and pigmentation are underway. 
 
The CMT4J mouse demonstrates that the mouse pigment pathway may 
be more sensitive than the nervous system to the loss of Fig4 function.  This is 
interesting, as the opposite is observed in CMT4J patients.  The patients have no 
known pigment abnormalities, but have a very severe peripheral neuropathy 
(Chow et al., 2007).  This may result from species differences in the peripheral 
nervous system.  Peripheral nerves in mouse are shorter than in human.  Vesicle 
trafficking through axons is most likely less of a burden in the shorter axons of 
mouse peripheral nerves.  This may make mouse peripheral nerves less 




As of this report, CMT4J mice from both lines are >7 months old and are 
unaffected as indicated by normal body weight and performance on 
neuromuscular tests.  These data indicate that the I41T allele still retains enough 
function to produce an intact, functioning nervous system in the mouse.  It 
remains to be seen if older CMT4J mice will develop neuropathy.  Other CMT 
mouse models are also much less severely affected than the human disease.  
For example, mouse models of CMT4B1 and CMT4B2 display only minor 
dysmyelination after one year of age (Bolis et al., 2007; Previtali et al., 2007).  If 
CMT4J mice develop late onset disease, study of these mice may facilitate in 
understanding the disease and development of a therapy.   
 
A thorough study is needed to properly characterize any subtle 
neurological defects.  Since CMT4J is a peripheral nerve disease, nerve 
conduction velocity (NCV) measurements should be taken from the CMT4J mice 
as they age.  Subtle NCV abnormalities are likely to be present before any 
movement disorder is displayed, signaling the onset of disease.  If there are no 
NCV abnormalities, then as the mice age, they should also be subjected to a 
battery of behavioral tests to monitor them for subtle neurological disorder.  Mice 
should be tested for neuromuscular abnormalities with the rotarod, hanging wire 
tests, and grip strength measurements.  Several mice at each time point should 
be evaluated histologically.  Subtle demyelination and axonal degeneration could 
be present in the peripheral nerves.  Neurons in the brain and motor neurons in 
the spinal cord should be monitored for signs of vacuolization, like those 
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observed in the Fig4-/- mice.  Though CMT4J patients do not display any brain 
degeneration, the Fig4-/- mice display severe brain degeneration.  To test for 
CNS function, mice should also be evaluated with cognitive tests, such as the 
Morris Water Maze.  This would determine if there is subtle brain degeneration in 
the CMT4J mice that might be missed by gross histology.   
 
Two independent transgenic lines were studied and both displayed no 
neurological deficits, but retained a pale coat color.  Analysis of multiple 
transgenic lines ensures that the results reported here are not due to insertional 
effects.  Expression of the transgene can vary between transgenic lines and 
further analysis of line Tg705 and Tg721 is needed to establish whether 
expression differences are present.  Quantitative gene expression such as real 
time PCR should be used to determine the levels of Fig4 expression in the 
nervous system and skin of CMT4J mice.  It is possible that over expression of 
the transgene in the nervous system is protecting CMT4J mice from 
degeneration.  This might not represent the human disease where only one copy 
of I41T is being expressed.  in situ hybridization analysis can be used to 
determine the spatial expression pattern of the transgene in brain and other 
somatic tissues. 
 
The CMT4J mouse is a partial rescue of Fig4-/-.  The CMT4J mouse has 
demonstrated that the I41T allele retains enough function to protect the mouse 
from early lethality and neurodegeneration in the context of these transgene 
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expression levels.  The pigmentation defect suggests that the I41T mutation 
disrupts PI(3,5)P2-related interactions that are essential for pigmentation.  
Further analysis of the CMT4J mouse will determine if it will be a good model of 
CMT4J pathogenesis in humans.   
 
It remains to be seen if the missense variant Fig4R905C has functional 
consequences in mouse and human.  The occurrence of the same mutation in 
two different species is not often observed.  In this case, the explanation 
probably lies in the fact that conversion of the arginine codon CGU to the 
cysteine codon UGU can occur by demethylation of the CpG dinucleotide in 
positions 1 and 2 of this codon.   CpG demethylation is a common molecular 
mechanism for mammalian mutations, and recurrent independent mutations are 
observed in unrelated patients with similar disorders, e.g. epilepsy patients with 
CGA (arginine) to TGA (stop codon) mutations in SCN1A (Kearney et al., 2006).  
There is no evidence of neurological disorder in WSB/EiJ mice.  Our cross with 
the Fig4 null allele also suggests that R905C does not affect neurological 
function or vacuolation of cells.  R905C cannot be tested in yeast because the C-
terminus of Fig4 is not well conserved between mouse and yeast.  Ongoing 
analysis will determine if R905C affects pigmentation. 
 
Here I have presented initial analysis of mouse models of two human 
FIG4 variants.  Both transgenic mice and naturally occurring variants could be 




Figure 3-1. Structure of I41T transgene.  The mouse Fig4 cDNA with the I41T 
mutation was cloned upstream of a CMV/ -actin promoter.  Arrows, genotyping 
primers.  pA, poly-A. 
 
 










Figure 3-2. Expression of Fig4 in transgenic lines.  RT-PCR analysis of 
transgene expression in brain RNA with 25 cycles.  Line Tg716 is similar in 
expression to wildtype (WT).  Tg705 and Tg721 have equal expression, but more 
than wildtype.  Fig4-/- has little to no expression.  Transgenic samples are from 
Fig4-/-, Tg+ mice.  Amplification was not due to genomic DNA contamination, as 
indicated by lack of amplification in ‘No RT’ gel below.  Reverse transcriptase 
was excluded from the ‘No RT’ reactions, any amplification would be from 
genomic DNA.  Arrows on transgene diagram indicate primers used for 
expression analysis.  Neg., negative control reaction lacking template. P, 





Table 3-1. Inheritance of transgene in Tg705 and Tg721 is consistent with 
one insertion site 
 
Tg+ (%) Tg- (%)
Tg705 (n=130) 50 50
Tg721 (n=108) 55 45
expected for 1 insertion site 50 50






Figure 3-3.  I41T transgene experimental breeding scheme.  Two generation 
breeding scheme to produce the experimental CMT4J mice.  Fig4-/- mice without 







Figure 3-4. Reduced body weight of Fig4-/- mice is rescued by the I41T 
transgene.  Rescue of body weight is evident in line Tg705 and Tg721.  There is 
no difference in body weight between control and Fig4-/-, Tg+ mice.  Control mice 
consisted of littermates with the following genotypes: Fig4+/+, Tg-, Fig4+/-, Tg-, 






Figure 3-5. Normal neuromuscular ability of Fig4-/-, Tg+ mice.  Mice were 
subjected to the wire hang test for neuromuscular ability.  The time spent 
hanging was recorded (0-60 seconds).  Fig4-/-, Tg+ mice were identical in ability 
to littermate controls.  Note the low number of animals from line Tg721.  (Line 
Tg705: Fig4-/-, Tg+: n=13; controls: n=21.  Line Tg721:  Fig4-/-, Tg+: n=4; controls: 
n=8).  Mice of different ages (1-7 months of age) and sex were combined for this 
analysis.  Control mice consisted of littermates with the following genotypes: 






Figure 3-6. Lethality of Fig4-/- is rescued by I41T transgene.  The survival of 








Figure 3-7. Fig4-/-, Tg+ mice have pale coat color.  4 month old Fig4-/-, Tg+ 
mice and a wildtype littermate.  Fig4-/-, Tg+ mice have dilute coat color similar to 





Figure 3-8. A FIG4 missense variant in a CMT patient.  a. Sequencing of exon 
23 from patient BAB1591 reveals the missense variant R905C.  c. R905C, in 
exon 23, is three residues from the c-terminus.  b. Residue arginine 905 is 






Figure 3-9. R905C is a SNP in mouse train WSB/EiJ.  a. Sequencing of exon 
23 from WSB/EiJ and C57Bl/6J mice.  b. Complementation test with the null 
allele of Fig4 on agouti coat color (agouti genotype, A/a).  c. Complementation 
test with null allele of Fig4 on black coat color (agouti genotype, a/a).   
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Materials and Methods 
Animals 
Fig4-/- mice were previously described (Chow et al., 2007) and are 
maintained on a mixed background comprised of 50% CAST/Ei and a mix of 
C57BL/6J, SJL, C3H and 129.  Transgenic founders were C57BL/6J/SJL F2.  
Transgenic founders were bred directly to Fig4+/- heterozygous mice (Figure 3-3).  
WSB/EiJ mice were ordered from the Jackson Lab (Bar Harbor, ME).  This 
research was approved by the University of Michigan Committee on Use and 




 The Fig4 cDNA was amplified by PCR from C57BL/6J brain cDNA using 
forward primer 5’ ACGCATGCTATGTGTCTGGTGTGCTGGAGGTCTG 3’ and 
reverse primer 5’ TCGCATGCAGTCCTTTACCAATGAGCTGCATC 3’.  These 
primers added Sph1 sites upstream and downstream of the cDNA.  PCR product 
was digested with Sph1 and cloned into the Sph1 site of the pCAG3z vector.  
The I41T mutation was inserted by site-directed mutagenesis of the pCAG3z-
FIG4 vector.  Sequencing confirmed the presence of I41T as well as the absence 
of PCR induced errors. 
 
Generation of transgenic mice 
 DNA from pCAG3z-FIG4 was isolated according to the Qiagen Maxi Prep 
Kit.  The vector was digested with BamHI.  The purified fragment containing the 
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cDNA construct was microinjected into (C57BL/6 X SJL)F2 mouse eggs and 
transferred to recipients by the University of Michigan Transgenic Animal Model 
Core.  Founders were identified by genomic PCR of tail DNA with a transgene 
specific forward primer, 5' TGCTGGTTATTGTGCTGTCTCATC 3’, and reverse 




 Genotyping was performed on genomic DNA from tail biopsies.  pale 
tremor mice were genotyped as previously described (Chow et al., 2007).  
Transgenic mice were genotyped using the same primers described for founder 
identification.  WSBEi/J genomic DNA was ordered form the Jackson Lab.  
Sequencing was performed at the University of Michigan Sequencing Core.  
WSB/EiJ mice are genotyped with forward primer, 5’ 
GAGGTTGCCCTTGGTTGGTGAAGC, and reverse primer, 5’ 
ACAAAATCTGGAAGACAACACTGG.  PCR product is subsequently digested by 
AluI endonuclease.   
 
RT-PCR 
 RNA was prepared from brain, subjected to DNAse treatment, and 
synthesized into first-strand cDNA.  Transgene expression was assessed with a 
forward primer in exon 18 and a reverse primer in exon 19 of Fig4.  RT-PCR was 
performed with various numbers of cycles to establish linear amplification.  The 





Neuromuscular strength was tested with the wire hang test (McKinney et 
al., 2008).  Mice were placed on a wire mesh and gently shaken so that the 
mouse firmly griped the wire.  The mesh was turned upside down and the trial 
ends when the mouse falls off or 60 seconds has elapsed.  Time spent hanging 
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MUTATION OF THE PI(3,5)P2 REGULATOR VAC14 CAUSES A LETHAL 




 Missense mutations offer a unique opportunity to determine the function of 
genes.  A single amino acid substitution often does not result in complete loss-of-
function.  Study of multiple amino acid substitutions can define multiple functions 
of a gene (Oliver et al., 2007).  An allelic series is a collection of organisms with 
different mutations in the same gene and can reveal unexpected function and 
phenotypes, as it is often difficult to predict, a priori, what a single amino acid 
change will do.  
 
Fab1, Vac14, and Fig4 regulate the levels of PI(3,5)P2.  PI(3,5)P2 is 
synthesized from PI3P by the kinase Fab1 (Cooke et al., 1998; Gary et al., 
1998).  Fig4 dephosphorylates PI(3,5)P2 to make PI3P.  Vac14 does not have 
enzymatic activity, but functions as a scaffolding protein and activator of Fab1 
activity (Bonangelino et al., 2002; Dove et al., 2002).  Loss of Vac14 results in 
large yeast vacuoles and abnormal PI(3,5)P2 levels.  Under basal conditions, 
Vac14 null yeast cells have undetectable levels of PI(3,5)P2.  Vac14 null cells 
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are also defective in hyperosmotic shock induced elevation of PI(3,5)P2 (Duex et 
al., 2006b).  Loss of Fig4 produces a phenotype that is similar to, but less severe 
than loss of Vac14.  
 
Complete loss of Vac14 in mouse results in severe neurodegeneration 
and perinatal lethality (Zhang et al., 2007).  Vac14 null mice display severe 
degeneration in the brain and peripheral ganglia, including the dorsal root ganglia 
(DRG) and trigeminal ganglia.  Hydrocephalus is also apparent in brains from 
Vac14 null mice.  Neurons and cultured fibroblasts from Vac14 null mice 
accumulate large cytoplasmic vacuoles of late endosome or lysosome origin.  
Importantly, Vac14 null fibroblasts display decreased levels of PI(3,5)P2 (Zhang 
et al., 2007). 
 
 Loss of Vac14 in mammalian cells is similar to loss of Vac14 in yeast.  
Both result in abnormal enlargement of late endosome/lysosome compartments 
as well as decreased production of PI(3,5)P2.  Loss of Fig4, the PI(3,5)P2 5-
phosphatase, in mouse closely resembles loss of Vac14, with similar 
neurodegeneration and cellular phenotypes.  These results suggest that Vac14 
and Fig4 function are well conserved between yeast and mammals.   
 
Fab1, Fig4 and Vac14 form a multi-protein complex in mammalian cells 
(Sbrissa et al., 2007), but little is known as to how these proteins interact and 
whether there are other components of this complex.  These interactions are very 
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intricate.  The presence of all of these proteins is required for proper functioning 
of the entire complex (Chow et al., 2007; Duex et al., 2006a; Duex et al., 2006b; 
Zhang et al., 2007).  Analysis of other mouse mutants in this pathway would 
further our understanding of these interactions, as well as the role of PI(3,5)P2 in 
the nervous system. 
 
To identify other mouse mutants of Fab1, Vac14, and Fig4, I searched the 
Neuromice database (http://www.neuromice.org) and the Jackson Lab Mutant 
Mouse Resource (JAX MMR, http://mousemutant.jax.org) for mutants with 
neurological and/or coat color defects.  I limited my search to the three 
chromosomes containing Fab1 (chr. 1), Vac14 (chr. 8), and Fig4 (chr. 10).  The 
mouse mutant infantile gliosis (ingls) was identified on mouse chromosome 8 
from the Jackson Lab Mutant Mouse Resource 
(http://mousemutant.jax.org/gliosis_paper.html).  ingls mice have pale coat color 
(Figure 4-1a), severe movement disorder, and lethality by 3 weeks of age.  ingls 
mice display severe hydrocephalus and vacuolization throughout the brain, 
including the cortex, thalamus, and brainstem.  Prior to the striking 
neurodegeneration, profound astrogliosis is apparent in the brain.  Interestingly, 
no degeneration in the spinal cord or dorsal root ganglia (DRG) is observed.  All 
other organs appeared to be unaffected (see results and 
http://mousemutant.jax.org/gliosis_paper.html).  These features are similar to 




ingls is a recessive mutation and was previously linked to mouse 
chromosome 8 between microsatellite markers D8Mit33 (98.6 Mb) and D8Mit200 
(117.2 Mb) (http://mousemutant.jax.org/gliosis_paper.html).  Vac14 lies within 
this 18.6 Mb nonrecombinant interval at 113.1 Mb.  The phenotype of ingls and 
presence of Vac14 within the nonrecombinant region led me to hypothesize that 
ingls is an allele of Vac14. 
 
Identification of additional mutant alleles of Fig4 and Vac14 will further our 
understanding of the role of these proteins and PI(3,5)P2 in the nervous system.  
Here I report the mouse mutant ingls is a new allele of Vac14. 
 
Results 
Identification of a Vac14 mutation in ingls 
Homozygous ingls DNA was ordered from the Jackson Lab.  Sequencing 
of all 19 exons of Vac14 revealed a missense mutation (c467 T>G) resulting in 
the amino acid substitution L156R (Figure 4-1b).  ingls arose on the DBA/2J 
inbred mouse line.  L156R is not present in DBA/2J mice (not shown), indicating 
that L156R is most likely the pathogenic mutation in ingls mice.  The L156R 
mutation is distinguished by genomic PCR and subsequent digest by the SacI 
endonuclease (Figure 4-1c).  Leucine 156 is evolutionarily invariant in 





Noncomplementation of Vac14-/- and ingls 
To provide additional evidence that Vac14 L156R is the mutation 
responsible for ingls, I performed a complementation test with a null allele of 
Vac14 (Vac14-/-) (Zhang et al., 2007).  Unaffected ingls/+ heterozygous mice 
were mated with unaffected Vac14+/- heterozygous mice.  All mice born with 
genotype Vac14L156R/- (25%) were severely affected, dying before 14 days of 
age.  Several mice died on P1, and the survivors were runted, diluted in color 
(Figure 4-2) and had a severe movement disorder.  All other genotypes were 
unaffected and appeared at the expected Mendelian ratio (Figure 4-2b).  ingls 
failed to complement the Vac14 null allele, confirming that the Vac14L156R allele is 
the pathogenic mutation. 
 
Phenotypic characterization of ingls (Vac14L156R/L156R) and Vac14L156R/- mice 
Homozygous ingls mice (referred to as Vac14L156R/L156R) and Vac14L156R/- 
mice display severe tremor and movement disorder.  Severe hydrocephalus was 
suggested by the domed heads of the mice.  This was confirmed with sagittal 
sections of brain from Vac14L156R/L156R and Vac14L156R/- mice (Figure 4-3).  Similar 
toVac14L156R/L156R mice (Figure 4-4), Vac14L156R/- mice displayed vacuolization 
throughout the brain (Figure 4-5), including the cortex, thalamus, cerebellar 
nuclei, and brainstem.  No degeneration was observed in DRGs or motor 
neurons in either mouse (Figure 4-6).  It should be noted that half the 
Vac14L156R/- mice born were dead on P1.  The analysis presented here is 
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representative of mice that survived past P1.   It is possible that mice dying on P1 
have much more severe neurodegeneration.  
 
Vac14L156R/L156R fibroblasts display lowered PI(3,5)P2 levels
 Vac14L156R/L156R brain extracts were probed for Vac14 protein expression.  
Homozygous Vac14L156R/L156R mice had equal amounts of Vac14 as their wildtype 
littermates (Figure 4-7a).  The Vac14L156R mutation does not result in unstable 
protein and may have altered function. 
 
To determine the functional consequences of the Vac14L156R mutation, 
fibroblasts were cultured from Vac14L156R/L156R and wildtype littermates.  The 
fibroblasts accumulated numerous large cytoplasmic vacuoles (Figure 4-7b, top 
right panel) similar to the Vac14 and Fig4 null fibroblasts (Chow et al., 2007; 
Zhang et al., 2007).  The abnormal vacuole phenotype was rescued by 
transfection with wildtype Vac14, further indicating that Vac14L156R is loss-of-
function. (Figure 4-7b).  Large cytoplasmic vacuoles are a consequence of 
abnormal PI(3,5)P2 levels (Ikonomov et al., 2002a; Ikonomov et al., 2001; 
Rutherford et al., 2006).  Vac14 null fibroblasts have significantly lower PI(3,5)P2 
levels (Zhang et al., 2007).  To test if Vac14L156R alters PI(3,5)P2 levels, 
phosphoinositides were measured from Vac14L156R/L156R and wildtype littermate 
fibroblasts.  Vac14L156R/L156R fibroblasts showed a significant decrease in 
PI(3,5)P2 levels as compared to wildtype cells (Figure 4-7c).  There was no 
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change in other phosphoinositide levels.  These results demonstrate that 
Vac14L156R and the Vac14 null allele have similar cellular phenotypes. 
 
Vac14L156R disrupts protein interaction in yeast 
To probe yeast Vac14 protein interactions with yeast Fab1 and Fig4, a 
directed yeast two-hybrid assay was undertaken.  Wildtype Vac14 interacted with 
itself.  Wildtype Vac14 also strongly interacted with Fig4 and Fab1 (Figure 4-8).  
To test if the Vac14L156R mutation affected these interactions, the same directed 
yeast two-hybrid was performed on the mutant Vac14 protein.  The homologous 
amino acid change in yeast is L149R.  Vac14L149R strongly interacted with 
wildtype Vac14 and Vac14L149R.  Interestingly, Vac14L149R failed to interact with 
Fab1.  Interaction with Fig4 was preserved (Figure 4-8).  These data indicate that 
the Vac14L156R mutation directly affects the assembly of the core protein complex 
that regulates PI(3,5)P2, by disrupting interaction with Fab1. 
 
Discussion 
I identified a new spontaneous missense mutation of Vac14 in the mouse 
mutant infantile gliosis (ingls).  Sequencing identified the amino acid substitution, 
L156R.  A complementation test with the Vac14 null allele confirmed that 
Vac14L156R is the pathogenic mutation in ingls (Vac14L156R/L156R). 
 
The phenotype of the ingls mouse is very similar to the Vac14 null mouse 
(Zhang et al., 2007).  Both display hydrocephalus and vacuolization throughout 
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the brain.  Interestingly, no degeneration is observed in ingls DRGs.  Severe 
degeneration of the DRGs is observed in the Vac14 null mouse (Table 4-1) 
(Zhang et al., 2007).  The difference in DRG degeneration suggests peripheral 
neurons are less sensitive to the loss of Vac14 function, while the CNS is highly 
dependent on Vac14 function.   
 
The compound heterozygous Vac14L156R/ - mouse allows us to evaluate 
whether gene dosage is important to Vac14 function.  Vac14L156R/- mice carry the 
null mutation and the Vac14L156R mutation, expressing 50% partial functioning 
protein.  Compound heterozygous mice display hydrocephalus and vacuolization 
throughout the brain.  No degeneration is detected in motor neurons and DRGs.  
Fifty percent partially functioning Vac14 has a similar effect as 100% partially 
functioning Vac14 on the central and peripheral nervous system. 
 
The degeneration in the nervous system of Vac14 -/-, Vac14L156R/ L156R, and 
Vac14L156R/- mice suggests that the CNS is very sensitive to loss of Vac14 
function (Table 4-1).  The DRGs are only affected by complete loss of Vac14.  
Despite the qualitative similarity of the CNS degeneration, the onset of 
neurodegeneration in the mutant mice varies.  Vac14 -/- mice die on P1 and CNS 
degeneration begins during embryogenesis (Zhang et al., 2007).  Vac14L156R/ 
L156R and Vac14L156R/ - mice both begin to develop hydrocephalus during the first 




While null mice die on P1, Vac14L156R/ L156R and Vac14L156R/ - mice have a 
range of survival from P1 to P21.  The range of survival time may be due to 
stochastic variation during development.  There may be a small developmental 
window when Vac14 is essential and the Vac14L156R protein may have enough 
function some of the time.  The variation could also be due to modifier genes.  
The Vac14L156R/L156R mice are congenic C57BL/6J, but the compound 
heterozygous mice are on a mixed background.  Evidence from studies with the 
Fig4 and Vac14 null mice suggests that modifier genes may affect survival 
(Chow CY, unpublished data).  Further analysis of the time course of 
degeneration in each of these mutant mice will shed light on this question. 
 
The milder phenotype of the ingls mice indicate that the Vac14L156R protein 
still has residual function and is not a null allele.  However, Vac14 null cells and 
Vac14L156R/L156R fibroblasts show 50% decrease in PI(3,5)P2 levels.  This 
demonstrates that the Vac14L156R mutation results in decreased PI(3,5)P2 
synthesis, most likely caused by loss of Fab1activation.  The decrease in 
PI(3,5)P2 levels is confirmed by the presence of large cytoplasmic vacuoles in 
Vac14L156R/L156R fibroblasts.   
 
Leucine 156 is evolutionarily invariant, suggesting that it is crucial for 
normal Vac14 function.  Because Vac14L156R does not destabilize the protein, I 
hypothesized that it may affect critical protein-protein interactions.  Leucine 156 
is part of a dileucine pair (Figure 4-1d and 4-9).  There are seven total conserved 
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dileucine pairs in Vac14 (Figure 4-9) (Dove et al., 2002).  Dileucine repeats have 
been shown to be involved in adaptor protein binding during clathrin-coated 
vesicle formation (Liu et al., 1998; Vowels and Payne, 1998).  Further analysis of 
the wildtype and Vac14L156R proteins is needed to determine if clathrin coated 
vesicle transport is abnormal in these mice. 
 
Dileucine motifs are also important for protein-protein interactions that are 
involved in sorting proteins to the endosome and lysosome (Bonifacino and 
Traub, 2003).  Directed yeast two-hybrid results suggest that L156R disrupts 
interaction within the PI(3,5)P2 complex.  Fab1 phosphorylates PI3P to make 
PI(3,5)P2 and the function of Fab1 requires Vac14 and Fig4.  Fig4 
dephosphorylates PI(3,5)P2 to make PI(3)P.  These three proteins have been 
shown to be in a complex in mammalian cells (Sbrissa et al., 2007) as well as in 
yeast (Rudge et al., 2004).  We show that wildtype yeast Vac14 interacts with 
yeast Fig4 and Fab1.  Vac14 also interacts with itself, confirming previous results 
(Dove et al., 2002).  When yeast Vac14L156R was tested for these interactions, it 
interacted with wildtype Vac14 and Fig4, as well as Vac14L156R.  Vac14L156R failed 
to interact with Fab1.  These data suggests that the pathogenicity of Vac14L156R 
results from loss of interaction with Fab1.  Fab1 may not be fully activated by 
Vac14L156R.  It remains to be seen whether this is also true in vivo. 
 
Leucine 156 also lies within a HEAT motif.  HEAT motifs are generally 
composed of two alpha helices which form a helical hairpin and a hydrophobic 
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core.  HEAT repeats are approximately 45 amino acids in length and are 
repeated in tandem.  HEAT repeats are often found in cytoplasmic proteins 
involved in vesicle transport and mediate protein-protein interactions.  Tandem 
arrays of HEAT motifs can fold into a parallel stack arrangement and proteins 
have been found to interact in the grooves or outside edges of the alpha helices 
(Andrade and Bork, 1995; Andrade et al., 2001a; Andrade et al., 2001b).  There 
are nine HEAT motifs in Vac14.  Leucine 156 resides in the second repeat 
(Figure 4-9).  It is possible that L156R disrupts the structure of the HEAT repeat 
and disrupts protein interactions that are critical for endosome to lysosome 
vesicle transport.  Loss of interaction with Fab1 may result from disruption of the 
dileucine repeat, the HEAT motif, or both.   
 
ingls mice were initially described and deposited in the JAX MMR because 
of significant astrogliosis.  Astrogliosis is often a secondary effect of 
neurodegeneration (Correa-Cerro and Mandell, 2007).  It remains to be seen 
whether the astrogliosis observed in ingls is primary or secondary.  Conditional 
deletion of Vac14 in astrocytes versus neurons will answer this.  Further analysis 
is needed to determine why the mutation Vac14L156R spares the DRGs, but not 
the brain.  Analysis of protein-protein interactions within the PI(3,5)P2 complex 
and discovery of other mouse mutants that affect the PI(3,5)P2 complex will 






Figure 4-1. A new allele of Vac14 in the ingls mouse.  a. ingls/ingls 
homozygous mice (L156R/L156R) are diluted in pigment and smaller than 
wildtype littermates.  b. Sequence of exon 4 from heterozygous ingls/+ genomic 
DNA.  c. Genotyping assay for the Vac14L156R mutation which destroys a SacI 
restriction site.  d. Leucine residue 156 is evolutionarily invariant from mammals 








Figure 4-2. ingls (Vac14L156R) does not complement the Vac14 null allele.   A 
complementation test was performed by crossing ingls/+ and Vac14+/- mice.  a. 
Compound heterozygotes Vac14L156R/- exhibit reduced size and diluted 
pigmentation in comparison with wildtype littermates.  b. Vac14L156R/- mice are 
born at Mendelian ratios, but survive for less than 2 weeks after birth.  All other 






Figure 4-3. Hydrocephalus in Vac14L156R/L156R and Vac14L156R/- brain.  Severe 
hydrocephalus is observed in Vac14L156R/L156R and Vac14L156R/- brain as compared 






Figure 4-4. Neurodegeneration in brain of Vac14L156R/L156R mice.  Significant 
neurodegeneration is observed in Vac14L156R/L156R mice.  Vacuolation of the brain 
is evident in regions listed.  Lower magnification images (10X) are shown for 
wildtype and Vac14L156R/L156R mice in the left and middle columns.  The right 
column shows higher magnification images (40X) of degenerated regions in 
Vac14L156R/L156R brain.  Sections are from P16 mice.  Arrow indicates 






Figure 4-5. Neurodegeneration in brain of Vac14L156R/- mice.  Significant 
neurodegeneration is observed in Vac14L156R/- mice.  Vacuolation of the brain is 
evident in regions listed.  Lower magnification images (10X) are shown for 
wildtype and Vac14L156R/- mice in the left and middle columns.  The right column 
shows higher magnification images (40X) of degenerated regions in Vac14L156R/- 
brain.  Sections are from P14 mice.  Arrow indicates degenerated tissue in 









Figure 4-6. No degeneration in DRGs and motor neurons in Vac14L156R/L156R 
Vac14L156R/- mice.  DRG and spinal motor neurons are shown.  No visible 
degeneration is detected in either tissue.  Arrows indicate motor neurons.  H&E.  







Figure 4-7. Vac14L156R causes a defect in the synthesis of PI(3,5)P2.  a. 
Vac14L156R/L156R mouse brain extracts have equal amounts of Vac14 protein 
compared with brain extract of wildtype mice. The specificity of the antiserum is 
demonstrated by the lack of signal in fibroblasts from Vac14−/− null mice.  GAPDH 
provides a loading control.  b. Vac14L156R/L156R fibroblasts are filled with large 
cytoplasmic vacuoles.  Expression of human Vac14-mCitrine in Vac14L156R/L156R 
fibroblasts rescues vacuolation phenotype.  >100 cells were counted. Arrows 
indicate transfected cells.  Scale bars, 20 microns. mCIT, mCitrine  c. PI(3,5)P2 
levels are decreased in Vac14L156R/L156R cultured fibroblasts.  Other 






Figure 4-8. Yeast Vac14L>R fails to interact with Fab1.  Directed yeast two-
hybrid analysis.  Wildtype yeast Vac14 and Vac14L149R corresponding to mouse 
L156R were tested for interaction with wildtype and mutant Vac14, as well as 
Fab1 and Fig4.  Wildtype Vac14 interacts with all proteins tested.  Vac14L149R 
interacts with itself, as well as wildtype Vac14 and Fig4.  Vac14L149R fails to 
interact with Fab1.  Top panel is experimental data.  Bottom panel is a control 
indicating that all yeast strains grow well on rich media.  The activating domain 
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* data for I41T/plt mice is as of 6 months of age. 
+ presence of degeneration 
- absence of degeneration 






Figure 4-9. Vac14 functional protein domains.  Vac14 has seven dileucine 
repeats and nine HEAT repeats.  The mouse Vac14 protein is 782 amino acids.  
Dileucine repeats are indicated by vertical lines and the amino acid position is 
below.  HEAT repeats are indicated by yellow boxes (numbered 1-9).  Table 
shows amino acid position of HEAT repeats in mouse and yeast Vac14.  Asterisk 
(*) indicates position of Vac14L156R mutation. 
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Materials and Methods 
 
Animals   
ingls mice were obtained on a C57BL/6J background from the Jackson 
Lab (stock number: 003095).  Vac14-/- mice (Vac14-geo/ -geo) were previously 
described (Zhang et al., 2007).  Briefly, Vac14-/- mice were created from gene-
trap embryonic stem cell line.  Vac14+/- mice are maintained on a mixed 
background of strain 129 and C57BL/6J.  Complementation test with Vac14-/- 
was performed by mating Vac14+/- X ingls/+.  Mice were genotyped as described 
below and monitored for phenotypes.  P1 is defined as the day of birth.  This 
research was approved by the University of Michigan Committee on Use and 
Care of Animals.  Animals were housed and cared for in accordance with NIH 
guidelines. 
 
Sequencing and genotyping   
ingls genomic DNA was ordered from the Jackson Laboratory. The Vac14 
coding sequence was sequenced with 19 primer pairs flanking the genomic 
sequence of all 19 exons.  PCR was carried out with the PCR Core Kit (Qiagen).  
PCR products were sequenced by the University of Michigan Sequencing Core.  
Vac14L156R is genotyped by restriction enzyme digest.  The Vac14L156R mutation 
destroys a SacI restriction site.  Genomic PCR is performed (Forward -
5'CAGCCAGTGGGAACAACCGTGTGA and Reverse-5' 
ACATAGACATGCAAGCAGGCAAAG).  PCR product is digested with SAC1.  
Wildtype mice are indicated by a 300 bp and 296 bp band.  Homozygous 
 
 96
Vac14L156R/L156R mice are indicated by a 596 bp band.  Heterozygous mice are 
indicated by the presence of all three bands. 
 
Cell Culture and immunoflouresence   
Primary fibroblasts were cultured as previously described (Chow et al., 
2007; Zhang et al., 2007).  Fibroblasts were obtained from P1 mice.  Transfection 
of fibroblasts and Western blot analysis was performed as previously described 
(Zhang et al., 2007).  Cells were transfected and 24 hours after transfection were 
fixed with 4% paraformaldehyde in PBS for 10 min at room temperature. 
Fluorescent cells were scored for the presence of vacuoles. Each data point is a 
mean of three independent experiments. For each experiment >100 cells were 
counted.  Images of cells were taken on an Axioscope 2 (Carl Zeiss 
MicroImaging, Jena, Germany) by using a LUCPlanFL N 40×/0.60 Ph2 objective 
with a DeltaVision microscope system. 
 
Phosphoinositide assays   
Levels of phosphoinositides were measured as previously described 
(Chow et al., 2007; Zhang et al., 2007).  Primary fibroblasts were starved in 
inositol-free DMEM for 12 h and labeled with myo-[2-3H]inositol for 36 h. Lipids 






Histopathology   
Mice were dissected and tissues were fixed in 10% buffered formalin.  
Histology was performed as previously described (Chow et al., 2007). 
 
Yeast two-hybrid analysis 
     For the pGAD or GBD fused Vac14p (Full length), Full length Vac14 DNA was 
amplified by PCR and subcloned into XmaI-SalI site. For the pGAD or GBD fused 
vac14 L149R, CTA(149 aa) was changed to CGA by site directed mutagenesis. 
For the pGBD fused Fab1p (807-1085 aa), a Fab1p DNA fragment amplified by 
PCR and subcloned into EcoRI-BglII site. For the pGBD fused Vac7p (394-918 
aa), Vac7 DNA fragment was amplified by PCR and subcloned into SmaI-SalI 
site. For the pGBD fused Atg18p (Full length), Full length Atg18 DNA fragment 
was amplified by PCR and subcloned into EcoRI-SalI site. For the pGBD fused 
Fig4p (Full length), Fig4 DNA fragment was amplified by PCR and subcloned into 
BasmHI-PstI site. Plasmids were cotransformed into the yeast strain PJ69-4A. 
Transformants were plated onto SC-Leu-Trp, replica-plated onto SC-Leu-Trp-
Ade-His + 3AT, and grown for 7 days at 24 ºC.  
 
Websites 
Neuromice database (http://www.neuromice.org)  
Jackson Lab Mutant Mouse Resource ( http://mousemutant.jax.org)  
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CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
In this concluding chapter I will summarize the important findings of my 
thesis work and explain how these results demonstrate the importance of 
PI(3,5)P2 function in yeast and mammals.  Previous yeast work will be reviewed 
and I will discuss how yeast data can inform future study of PI(3,5)P2 in 
mammals.  I have shown that mutations in the PI(3,5)P2 pathway cause human 
neurological disease.  I will discuss the different human diseases that I have 
screened and I will also propose other human diseases that warrant 
investigation.   
 
PI(3,5)P2 in mammals and yeast 
I have described two new mouse mutants in the PI(3,5)P2 pathway, pale 
tremor and ingls.  pale tremor is a null allele of Fig4 and ingls is a missense 
mutation in Vac14.  I also contributed to characterization of a third mutant, the 
Vac14 null mouse (Zhang et al., 2007).  Together, these three mouse mutants 
provide new information regarding the importance of PI(3,5)P2 to the nervous 
system.  pale tremor and ingls also demonstrate the importance of PI(3,5)P2 
signaling to coat pigmentation.  These mutants are the first descriptions of 
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perturbed PI(3,5)P2 synthesis in an in vivo mammalian system and demonstrate 
that PI(3,5)P2 regulation is critical to mammals. 
 
 In yeast, loss of Fab1, Vac14, or Fig4 result in similar phenotypes, 
with differing severities.  The entire complex is important and each individual 
protein must function within the PI(3,5)P2 complex.  Fab1 phosphorylates PI3P 
to make PI(3,5)P2.  Fig4 dephosphorylates PI(3,5)P2 to PI3P.  Vac14 activates 
Fab1 and is required for Fig4 function (Figure 5-1).  Loss of any of these three 
proteins results in an enlarged vacuole, altered basal PI(3,5)P2 levels (except 
Fig4), and altered PI(3,5)P2 levels in response to hyperosmotic shock (Dove and 
Johnson, 2007).  Loss of Fab1 is the most severe, followed by loss of Vac14.  
Loss of Fig4 displays the least severe phenotype (Duex et al., 2006b). 
 
pale tremor, ingls and the Vac14 null mouse mutants show defects in late 
endosome/lysosome compartments as indicated by fibroblasts that accumulate 
enlarged cytoplasmic vesicles that are of lysosomal origin.  This closely mimics 
the enlarged vacuole defect in yeast (Dove and Johnson, 2007), as the vacuole 
is the yeast equivalent of a mammalian lysosome.  These mouse mutants also 
display significant decreases in PI(3,5)P2 levels.  This is similar to the yeast 
phenotype of reduced basal and reduced hyperosmotic shock-induced levels of 




The pale tremor (Fig4 null) phenotype is the least severe of the three 
mutant mice, corresponding to the yeast data where loss of Fig4 results in a mild 
phenotype.  Fig4 null mice survive to six weeks and brain degeneration does not 
begin until age P7.  Only 40% of cultured Fig4 null fibroblasts vacuolate.  On the 
other hand, the Vac14 null mouse dies on P1 and brain degeneration begins 
during embryonic development.  The percentage of Vac14 null fibroblasts that 
vacuolate approaches 100%.  ingls is a missense mutation and not a null allele of 
Vac14.  ingls neurodegeneration is less severe than the Vac14 null allele and 
survival ranges between P1 and 3 weeks of age.  The mouse mutants described 
demonstrate that loss of Vac14 is more severe than loss of Fig4, similar to 
observations in yeast. 
 
PI(3,5)P2 and the nervous system 
 The selective importance of PI(3,5)P2 to the nervous system could not 
have been predicted from previous studies in yeast.  All three mutants display 
severe neurodegeneration.  In the Fig4 null and Vac14 null mice, degeneration is 
present in the central and peripheral nervous system.  In the dorsal root ganglia 
(DRG), the majority of neurons accumulate large cytoplasmic vacuoles, similar to 
the vacuoles in cultured fibroblasts.  Interestingly, DRG neurons from ingls do not 
degenerate.  Vacuolated neurons are present in the brain of these three mice, 
but they are rare and can only be found early in disease.  Severe degeneration in 
the CNS is indicated by the spongiform appearance of the brain tissue (empty 
spaces in the tissue due to loss of neurons).  Spinal motor neurons are affected 
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late in disease in the pale tremor mice.  Vac14 null and ingls mice do not display 
vacuolated motor neurons, but this might be due to the shorter life span of these 
two mutants.    
 
The small number of vacuolated neurons visible in the brain contrast with 
the large amount of degeneration observed.  Vacuolated neurons may be a 
transient stage prior to cell death.  In addition, the spongiform degeneration may 
result from axon loss due to the death of neurons that project to affected regions.  
DRG pathways extend from the ganglia, through the spinal cord, brainstem, 
thalamus and cortex (Wallengren, 2005).  Extensive degeneration is observed in 
all these regions and may be secondary to the loss of DRG neurons.  
 
 PI(3,5)P2 is a ubiquitous signaling molecule required for endosome and 
lysosome trafficking.  It is unclear why perturbation of PI(3,5)P2 metabolism 
specifically affects neurons, while other tissues appear unaffected.  Many other 
neurological diseases result from dysfunction of ubiquitous genes, including 
many forms of CMT (Niemann et al., 2006), Huntington’s disease (Walker, 2007), 
and Alzheimer’s disease (Zhang and Xu, 2007).  Neurons are post-mitotic, thus 
most neurons that die are not replaced, in contrast to other somatic tissues.   
 
Neurons are very metabolically active and require constant protein 
synthesis to maintain long dendrites and axons (Kennedy and Ehlers, 2006).  
Sensory neurons in the DRG and motor neurons in the anterior horn of the spinal 
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cord have long axons, up to a meter in some instances.  These long processes 
require constant turnover of membrane elements and receptors.  Vesicle 
trafficking is critical to this process.  Proteins and lipids are synthesized in the 
soma and packaged into cytoplasmic vesicles which are delivered through the 
axon to the target, so-called anterograde vesicle trafficking.  Proteins and lipids 
are recycled as well.  Receptors and surface proteins are endocytosed and 
delivered back into the soma, where they are degraded.  Signaling receptors and 
growth factors are also endocytosed and delivered to the soma to induce 
signaling that ultimately results in gene expression and growth of an axon.  
Retrograde trafficking moves cargo from the distal processes and nerve 
terminals to the soma.  Perturbed neuronal trafficking is implicated in several 
forms of CMT (Niemann et al., 2006) and ALS (Pasinelli and Brown, 2006; 
Schymick et al., 2007). 
 
 The three mouse mutants described allow us to investigate whether 
PI(3,5)P2 signaling is required for anterograde or retrograde trafficking.  We 
hypothesized that because PI(3,5)P2 controls trafficking between endosomes 
and lysosomes, neurodegeneration in the pale tremor mouse may be a result of 
perturbed axon trafficking.  Two tests of this hypothesis have been carried out.   
Localization of sodium channel Nav1.6 involves anterograde trafficking of newly 
synthesized channels to the nodes of Ranvier.  Localization of Nav1.6 in sciatic 
nerve appears normal in pale tremor mice (L. Sharkey, unpublished 
observations).  Dr. Michael Q. Kemp (Michigan State University) observed that 
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the rate of retrograde axonal transport in sciatic nerve is also normal in pale 
tremor mouse, as assessed by transport of horseradish peroxidase from injected 
muscle to motor neuron soma in the ventral spinal cord (personal 
communication).  Enlarged cytoplasmic vacuoles do not accumulate in the axons 
of DRG and motor neurons (Zhang et al., 2008).  Enlarged vesicles are restricted 
to the soma.  This preliminary data suggests that there are no major defects in 
anterograde or retrograde trafficking.  Additional measurements of neuron-
specific processes might reveal the basis for the particular sensitivity of neurons 
to abnormal PI(3,5)P2 levels. 
 
 The disease in the pale tremor mouse is classified as a neuronopathy.  
The neuron soma is first affected and axon loss is secondary.  It is clear that 
neurons are primarily affected because they accumulate large cytoplasmic 
vacuoles.  However, as in many neurodegenerative diseases, it is unclear 
whether astrocytes are also dysfunctional and contribute to disease.  Mutations 
in MTMR2 cause CMT4B1, a peripheral neuropathy.  Conditional deletion of 
Mtmr2 revealed that dysfunction of astrocytes was both necessary and sufficient 
to recapitulate the disease (Bolis et al., 2005).  Furthermore, astrocytes have 
been shown to modulate disease severity in ALS caused by mutations in SOD1, 
despite being a primary motor neuron disease.  SOD1 mutant astrocytes secrete 
an unknown toxic factor that kills wildtype motor neurons.  Wildtype astrocytes 
protect SOD1 mutant mice and prolong survival (Cassina et al., 2008; Di Giorgio 
et al., 2007; Nagai et al., 2007; Yamanaka et al., 2008).   
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 The ingls mouse was first identified because of extensive astrogliosis.  It 
remains to be seen whether this is primary or secondary to neurodegeneration.  
Conditional deletion of Fig4 or Vac14 in neurons and astrocytes will define the 
role of astrocytes in PI(3,5)P2-related neurodegeneration. 
 
PI(3,5)P2 and other tissues 
 The pale tremor mouse displays diluted pigment and cell loss in the 
spleen.  Both of these issues merit further investigation.  Fibroblasts vacuolate in 
culture, but do not appear to vacuolate in vivo.  Macrophages also vacuolate in 
culture (S. Yoshi and J. Swanson, unpublished observations).  Hippocampal 
neurons, which are unaffected in vivo, vacuolate when cultured, as well (Chow et 
al., 2007).  These observations suggest that latent endosomal/lysosomal 
dysfunction exists in all cells.  Culture conditions may lack growth factors or 
nutrients that prevent vacuolation in vivo.  Further analysis of cellular phenotypes 
due to loss of PI(3,5)P2  may be facilitated by using easily cultured cells, like 
fibroblasts, rather than neurons. 
 
The mouse as a tool to study PI(3,5)P2  
Both loss-of-function Fig4 and Vac14 mutations demonstrate the 
importance of PI(3,5)P2 in the mammalian nervous system.  However, these 
mutations do not provide information about the intricacies of the interactions of 
PI(3,5)P2 regulatory proteins.  To find other mutations in this pathway, I searched 
for mouse mutants similar to pale tremor.  I searched mouse mutant databases 
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(http://neuromice.org/ and http://mousemutant.jax.org/ ) for mutants with 
neurological and coat color abnormalities.  The unique pattern of 
neurodegeneration in pale tremor, combined with diluted coat color, made the 
overall phenotypic description good search criteria.  I identified ingls using this 
phenotypic information.  ingls was first observed at the Jackson Lab in 1991, but 
remained uncloned for >15 years.  The description of ingls was nearly identical to 
pale tremor, suggesting that it might have a mutation affecting PI(3,5)P2 
metabolism.  By careful analysis, I identified Vac14 in the nonrecombinant 
region.  Together, all this suggested to me that ingls might be an allele of Vac14.  
Experimental analysis confirmed this. 
 
 Many mouse mutants have been phenotypically characterized, but have 
not been genetically mapped.  Both spontaneous and chemical induced mutants 
are described in various databases such as at the Jackson Lab and Neuromice 
(see above).  By adopting a phenotype driven approach, one is guaranteed to 
find gene mutations that affect the phenotype of interest.  Careful phenotypic 
analysis of cloned mouse mutants is important for identifying new mutants.  This 
strategy has already proven to be successful and may continue to yield new 
mouse mutants involved in PI(3,5)P2 metabolism.  
 
 There has been more than a decade of research in the yeast PI(3,5)P2 
pathway.  This work is a rich resource for understanding the role of PI(3,5)P2 in 
the mammalian nervous system and human disease.  Structure and function 
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studies have been carried out for many of the yeast proteins.  This knowledge 
can be directly translated to study of the mammalian system.  These studies and 
how they may inform the study of PI(3,5)P2 in mouse will be discussed. 
 
Homologs of several yeast PI(3,5)P2-related proteins exist in mammals 
(Figure 5-1).  There is one homolog for Fab1, Vac14, and Fig4 in mammals.  In 
yeast, Vac7 is the major activator of Fab1.  Vac7 is crucial for Fab1 function and 
loss of Vac7 results in a similar phenotype as loss of Fab1.  There is no 
recognizable homologue of Vac7 in mammals (Gary et al., 2002).  It remains to 
be seen whether another mammalian protein replaces Vac7, or if the Vac14/Fig4 
complex is the main Fab1 activator.  Atg18 modulates PI(3,5)P2 levels and is a 
PI(3,5)P2 effector in yeast.  There are at least four mammalian homologs of 
Atg18, WIPI1-4 (Dove et al., 2004).   
 
 Mutagenesis in yeast has identified important amino acid residues in 
several of these proteins.  Both gain-of-function and loss-of-function mutations 
have been described.  Fig4 is the PI(3,5)P2 5-phosphatase, yet null Fig4 yeast 
cells have a net decrease in PI(3,5)P2 (Duex et al., 2006a).  This surprising 
finding suggests that Fig4 also functions as a regulator of Fab1.  It has been 
hypothesized that Fig4 dephosphorylates Fab1 in addition to PI(3,5)P2 (Duex et 
al., 2006a).  These predictions were validated with a mutation in Fig4.  The 
mutation Fig4G519R is located 44 amino acids downstream of the catalytic site 
(yeast: 467Cx5RT) in the SAC phosphatase domain (Table 5-1)(Gary et al., 2002).  
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This mutation resulted in increased basal levels of PI(3,5)P2, indicating it has 
reduced PI(3,5)P2 phosphatase activity.  In response to hyperosmotic shock, 
wildtype yeast display a 20 fold increase in PI(3,5)P2 by 10 minutes.  This high 
level of PI(3,5)P2 is quickly returned to basal levels over the next 10 minutes.  In 
response to hyperosmotic shock, the Fig4G519R strain displayed deficits in the 
initial increase of PI(3,5)P2 (phosphorylation) and failed to completely return to 
basal levels (dephosphorylation) (Duex et al., 2006b).  This demonstrates that 
the SAC phosphatase activity is crucial for both production and turnover of 
PI(3,5)P2.  A second mutation in the catalytic site of the SAC domain, Fig4D469N, 
has a similar phenotype (Table 5-1) (Duex et al., 2006b). 
 
 Another mutation in yeast Fig4 identified a domain that is required for 
localization of the protein to the vacuole.  A truncated form of Fig4 was 
expressed in yeast by deleting the last 118 amino acids (Table 5-1).  This protein 
did not localize to the vacuole and was completely cytoplasmic (Rudge et al., 
2004).  Further analysis was not conducted, but this observation indicates that an 
interaction at the carboxyl terminus with a protein or a lipid is responsible for 
subcellular localization of Fig4. 
 
 The majority of mutations in Fab1 affect the kinase domain and kinase 
activity.  Fab1 also has a FYVE domain that binds PI3P and a CCT chaperone 
domain thought to be involved in protein-protein interactions.  Mutants with 
reduced or no kinase activity are similar to Fab1 null yeast (Table 5-2).  These 
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mutations are located in kinase-specific catalytic motifs.  They display reduced or 
undetectable levels of PI(3,5)P2 levels and grossly enlarged vacuoles (Gary et 
al., 1998; Michell et al., 2006). 
 
 In yeast, Fab1 cannot function without Vac7, Vac14, and Fig4.  This 
suggests that Fab1 is not constitutively active.  A study to find Fab1 mutants that 
bypass the need for Vac14 or Vac7 yielded many mutations with constitutive 
kinase activity (Table 5-2) (Duex et al., 2006b).  These mutants rescued the 
enlarged vacuole phenotype and fell into two categories.  One group of mutations 
rescued Vac14 null yeast cells.  The second group rescued both Vac7 null and 
Vac14 null cells.  Both groups of mutations display elevated basal PI(3,5)P2, but 
hyperosmotic shock-induced PI(3,5)P2 levels were not affected (Duex et al., 
2006b).  This demonstrates that the regulation of basal and stress-induced levels 
of PI(3,5)P2 differs.  Mutations that rescued Vac7 null and Vac14 null cells had 
higher basal levels of PI(3,5)P2 as compared to those that could only rescue 
Vac14 null cells (Duex et al., 2006b), consistent with more severe phenotypes 
observed in Vac7 null yeast.  All the mutations that can bypass Vac14 or Vac7 
reside in amino acids that are not directly related to kinase activity.  Several 
mutations are outside of the kinase domain, suggesting these mutations activate 
kinase activity via protein interactions. 
 
 The yeast mutations in Tables 5-1 and 5-2 may shed light on PI(3,5)P2 
function in mammals.  Loss-of-phosphatase mutations in Fig4 should resemble 
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pale tremor (Fig4 null).  These mutations may reveal other Fig4 functions 
because the protein would still be intact and expressed.  The SAC domain is the 
only recognizable domain in Fig4 and is highly conserved between mouse and 
yeast.  It is likely that other mutations in the SAC domain would resemble null 
alleles.   
 
 The lack of additional recognizable domains in Fig4 makes it difficult to 
predict what kind of mutations would cause disease.  The SAC domain 
comprises 50% of the Fig4 protein.  The N-terminal ~150 amino acids upstream 
of the SAC domain are well conserved, containing stretches of invariant or nearly 
invariant residues between yeast and mouse.  Mutations in this region might be 
instructive to identify new protein-protein interactions.  I performed a yeast two-
hybrid experiment with the N-terminus of Fig4 and identified several relevant 
protein interactions involved in vesicle transport (data not shown).  These are in 
the process of being validated.  Mutations in the N-terminus may disrupt these 
interactions. 
 
The C-terminal ~400 amino acids downstream of the SAC domain are less 
conserved.  Nonetheless, the last 118 amino acids in yeast are critical for 
subcellular localization to the vacuole (Rudge et al., 2004).  It may be instructive 
to construct hybrid proteins in which the C-terminus of the mouse and yeast Fig4 
proteins is switched.  This may indicate whether the interactions required for 
localization are conserved.  Finally, human Fig4 contains several motifs known to 
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interact with endosomal proteins (49LVIID 351DPF, and 656FXDXF) (Sbrissa et al., 
2007).  Mutations in these motifs may reveal new protein-protein interactions.  
This could be tested with wildtype and mutated Fig4.  Loss of interaction and 
abnormal cellular phenotype would establish the importance of these motifs to 
Fig4 function. 
 
Mouse mutants of Fab1 have not been reported and analysis has been 
limited to in vitro cell culture studies utilizing siRNA knockdown or over 
expression of a kinase-dead mutant.  These studies revealed defects in the late 
endosome/lysosome pathways as well as reduced PI(3,5)P2 levels, as predicted 
from the yeast work.  These experiments also suggested that Fab1 and 
PI(3,5)P2 may affect insulin signaling by perturbing insulin receptor trafficking 
(Ikonomov et al., 2002b) and osmotic response (Sbrissa et al., 2002).  Knockouts 
of Fab1 have been reported in C. elegans (Nicot et al., 2006) and drosophila 
(Rusten et al., 2006).  Both result in embryonic lethality, enlarged vesicles, and 
abnormalities in the endosome/lysosome pathway. 
  
 Heterozygous mutations of human FAB1 cause François-Neetens 
mouchetée fleck corneal dystrophy (CFD) (Li et al., 2005b).  CFD is an 
autosomal dominant disease and the majority of mutations are protein truncating.  
Reported mutations in FAB1 reside in or around the CCT chaperone domain (Li 
et al., 2005b).  It is unclear as to the significance of the location of these 
mutations, as studies in yeast and mammalian cells have focused on the kinase 
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domain of Fab1.  Yeast two-hybrid experiments should be carried out to establish 
protein-protein interactions that the CCT domain might facilitate. 
 
The FAB1 mutation, K1103R, is the only missense mutation reported in 
CFD (Li et al., 2005b).  Lysine 1103 is 39 amino acids downstream of the CCT 
domain and is evolutionarily invariant in vertebrates and yeast.  The yeast 
mutation Fab1-1 (G864E) resides in an invariant residue in the CCT domain 
(Table 5-2) (Michell et al., 2006).  G864E causes inability to activate in response 
to hyperosmotic shock, suggesting that it is disrupting a protein interaction that is 
required for activation, but not kinase activity (Michell et al., 2006).  Studying 
K1103R and G864E in mammalian cells or transgenic mice could identify protein 
interactions that are essential for Fab1 activation in mammals.  These mutations 
may be similar to Vac14 or Fig4 mutants, where Fab1 is not activated. 
 
 A mouse with a null allele of Fab1 is predicted to be similar to, but more 
severely affected than, Fig4 and Vac14 null mice since the net result of loss of 
Vac14 or Fig4 is decreased PI(3,5)P2.  Fab1 null mice and cells would 
demonstrate the effect of complete loss of PI(3,5)P2.  Fab1 null cells would be 
expected to vacuolate and null mice would be embryonic lethal, as no PI(3,5)P2 
would be synthesized.  Reduced kinase activity mutants may establish a minimal 




 Hyperactive Fab1 mutations present an interesting opportunity.  It is 
unknown what the consequence is of increased levels of PI(3,5)P2 in the 
mammalian nervous system.  Increased levels could result in perturbed vesicle 
trafficking and lead to human disease.  It is difficult, a priori, to predict what kind 
of disease a hyperactive Fab1 mutation would cause. Hyperactive Fab1 
mutations have been studied in yeast (described above and Table 5-2) and these 
mutations can be engineered into a mouse Fab1 transgene.  Transgenic mice 
expressing a hyperactive Fab1 mutation would model the dominant nature of 
constitutive activity.  These mice would inform the search for human diseases 
that are caused by hyperactive FAB1 mutations. 
 
 Hyperactive Fab1 mutants could determine if reduction in PI(3,5)P2, per 
se, is responsible for phenotypes observed in Fig4-/-, Vac14-/-, and 
Vac14L156R/L156R mice.  All three mutants display reduced levels of PI(3,5)P2 in 
cultured fibroblasts, but this may be secondary to another unidentified function of 
this pathway. Some phenotypes observed in the mutant mice may be due to loss 
of protein interactions rather than loss of PI(3,5)P2.  A transgenic mouse 
expressing a hyperactive Fab1 protein could be bred onto the background of 
Fig4-/-, Vac14-/-, and Vac14L156R/L156R mutant mice.  If this rescues the mouse 
phenotypes, then it would be clear that lower levels of PI(3,5)P2 are responsible 
for the disease observed in these three mouse mutants.  If certain phenotypes 
remain, it would indicate that other unknown functions or interactions of this 
complex contribute to the disease phenotype. 
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Two Vac14 mutants have been studied in mice, the null and the ingls 
mutation, Vac14L156R.  Vac14 does not have well defined protein functional 
domains.  Vac14L156R changes a dileucine repeat and may disrupt a HEAT motif.  
We have already established that Vac14L156R disrupts interaction with Fab1 in a 
directed yeast two-hybrid analysis.  Other yeast two-hybrid studies comparing 
wildtype and mutated Vac14 may yield other interactions that Vac14L156R may 
have interrupted.  Seven dileucine repeats are found in Vac14.  Dileucine repeats 
are involved in protein interactions important for endocytic vesicle trafficking 
(Bonifacino and Traub, 2003; Liu et al., 1998; Vowels and Payne, 1998).  
Perhaps additional mutations in these residues would reveal new protein 
interactions as well.  The ingls mouse demonstrates that missense mutations in 
Vac14 can affect certain, but not all phenotypes observed in the null mouse.   
DRGs are severely degenerated in the null, but not in the ingls mouse.  Since it is 
difficult to predict which amino acids would be most important to Vac14 function, 
spontaneous mouse mutants of Vac14 may be the most useful.  New alleles of 
Vac14 can be identified by screening ENU mutagenized ES cell lines 
(http://www.mmrrc.org/distribution/UNC_Library.html).   
 
The PI(3,5)P2 pathway and human disease 
I established that dysfunction in the PI(3,5)P2 pathway results in severe 
neurodegeneration in the mouse and hypothesized that a human disease with 
severe degeneration of the CNS and PNS observed in the pale tremor mouse, 
would be prenatal or perinatal lethal.  We therefore focused on the peripheral 
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neuropathy.  The pale tremor peripheral neuropathy closely mimics severe forms 
of Charcot-Marie-Tooth disease (Bernard et al., 2006; Dubourg et al., 2006).  I 
identified four CMT patients with recessive mutations in FIG4.  Four percent of 
the patients I screened carried mutations in FIG4, suggesting that a significant 
number of CMT patients carry FIG4 mutations (Chow et al., 2007).  Continued 
screening of CMT patients will establish the contribution of FIG4 mutations to 
CMT.   
 
 Because FIG4 was found to contribute to CMT, we hypothesized that 
mutations in VAC14 would also result in CMT.  We screened the same 95 CMT 
patients for mutations in VAC14, however, no mutations were identified (Table 5-
3).  Further screening is needed to establish whether VAC14 contributes to CMT.  
Mutations in FAB1 might also cause CMT.  Haploinsufficiency for FAB1 results in 
François-Neetens mouchetée fleck corneal dystrophy (Li et al., 2005b).  This 
suggests that FAB1 CMT would be recessive.  We have not yet screened CMT 
patients for mutations in FAB1. 
 
 My mutation screens have yielded human FIG4 missense variants that 
warrant further study (Table 5-4 and 5-5).  The I41T mutation was identified in 
four CMT patients and I have developed a mouse model carrying I41T.  It 
remains to be seen if this will be an accurate model of CMT4J.  In addition to this, 
I have identified several other missense mutations in CMT patients and in a 
screen of patients with motor neuron disease (Chow CY, unpublished results) 
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(Table 5-4).  The N-terminus and SAC domains of yeast and human FIG4 are 
well conserved, indicating that these protein domains are important for function.  
Yeast is a good model for evaluating the functional effects of missense variants 
identified in human FIG4.  We have tested several human N-terminal and SAC 
domain missense variants in yeast (Table 5-4).  Fig4 null yeast cells display an 
enlarged vacuole phenotype.  The vacuole appears swollen and is easily 
visualized when labeled with the lipiphilic dye FM4-64.  A construct carrying the 
yeast Fig4 gene with the corresponding missense mutation was tested for its 
ability to rescue Fig4 null yeast cells.  A rescued cell has a normal wildtype-sized 
vacuole.  Many cells are counted and the number of rescued and non-rescued 
cells was compared to Fig4 null cells and cells rescued with a wildtype construct.  
Populations of Fig4 null cells rescued with a wildtype construct have ~90% cells 
with normal, small vacuoles, while FIG4 null populations have ~5% cells with 
normal, small vacuoles.  PI(3,5)P2 levels should also be measured from these 
cells, but this has not been done.  Several of the missense mutations identified in 
patients have been shown to rescue the null phenotype (data not shown) 
indicating that they retain wildtype levels of function. 
 
 C-terminus mutations are more difficult to test because it is not well 
conserved between human and yeast.  Due to lack of conservation, they will 
likely require testing in a mammalian system.  Mutant Vac14 fibroblasts can be 
rescued by transfection with a wildtype Vac14 construct (Zhang et al., 2007).  
This suggests that Fig4 null fibroblasts can also be rescued by transfection of 
 
 118
wildtype Fig4.  Mutant Fig4 constructs can be transfected into Fig4 null cells to 
assess the ability of the mutant protein to rescue the vacuolization phenotype.  
This technique warrants further development.  
 
I identified a FIG4 C-terminal missense variant, R905C, in one CMT 
patient and in the mouse strain WSB/EiJ (Chapter III).  Experiments are 
underway to establish if R905C is a partial functioning allele in WSB/EiJ mice.  
R905C does not seem to affect the nervous system or cellular vacuolation, but it 
remains to be seen if it affects pigmentation. 
 
To extend our knowledge of PI(3,5)P2 related diseases, it will be important 
to continue to screen for mutations in FIG4, VAC14 and FAB1.  Besides CMT, I 
have screened several other diseases (Table 5-3 and 5-4).  Centronuclear 
Myopathy (CNM) results in hypotonia, weakness and early lethality.  CNM is 
characterized by hypotrophic muscle fibers and centrally placed nuclei in muscle 
cells (Pierson et al., 2005).  The most common form of CNM is caused by 
mutations in myotubularin (MTM1), a PI3P and PI(3,5)P2 3-phosphatase 
(Pierson et al., 2005).  MTM1 is related to MTMR2 and MTMR13 which cause 
CMT4B1 and CMT4B2, respectively (Robinson and Dixon, 2006).  Mutations in 
DNM2, a phosphoinositide binding protein, cause both CNM and CMT1DB 
(discussed in Chapter I).  These data suggests that dysfunction of FIG4 may 
cause CNM as well.  I obtained nine CNM samples from Dr. Jim Dowling 
(University of Michigan) to screen.  No new variants were identified in this small 
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group of patients (Table 5-3).  A more comprehensive screen is needed to 
establish whether mutations in FIG4 contribute to CNM.  VAC14 and FAB1 
should also be screened in these samples.   
 
The CMT disease in one of the patients with FIG4 mutations is primarily 
motor in origin (Zhang et al., 2008).  While there is degeneration of the sensory 
nerves, the clinical disease primarily affects motor abilities and degeneration of 
the motor nerves is present (Zhang et al., 2008).  Degeneration in both motor 
nerves and motor neurons is observed in the pale tremor mouse (Chow et al., 
2007).  This prompted me to obtain samples from 26 CMT patients with a 
primarily motor disease from Dr. Michael Shy (Wayne State University).  I 
screened these 26 samples, but found no mutations (Table 5-3).  Further 
screening of motor-specific CMT is warranted. 
 
To date, we have not identified a human disease that completely 
recapitulates the neurological disease and pigment abnormalities of the pale 
tremor mouse.  A literature search identified two reports of patients with a 
neurocutaneous syndrome (Buoni et al., 2006; Zannolli et al., 2008).  These 
patients have many neurological defects, including speech delay, mental 
retardation, and epilepsy.  They also displayed pigmentation abnormalities and 
vacuolation within melanocytes, keratinocytes, Langerhans cells, and fibroblasts, 
similar to the pale tremor and Vac14 null fibroblasts.  I sequenced FIG4 in both 
patients, but did not identify any mutations.  We also sequenced VAC14 and no 
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mutations were found (Table 5-3).  This indicates that coding mutations do not 
cause this unique syndrome, but does not rule out regulatory mutations in FIG4 
or VAC14.  FAB1 has not been screened in these samples. 
 
I searched the OMIM database (Online Mendelian Inheritance in Man) for 
human diseases that mapped to the chromosome regions that contain FIG4 (chr. 
6q21), VAC14 (chr. 16q22.1), and FAB1 (chr. 2q33.3).  The search identified 
spinocerebellar ataxia 4 (SCA4).  The SCA4 nonrecombinant region spans 
chromosome 16q22.1 and includes VAC14.  SCA4 presents with ataxia and 
peripheral sensory axonal neuropathy (Flanigan et al., 1996).  The sensory 
neuropathy resembles CMT.  We obtained a sample from the SCA4 family from 
Dr. Louis Ptacek (UCSF) and I sequenced the VAC14 coding exons, but did not 
identify a VAC14 mutation (Table 5-3).  Again, a VAC14 regulatory mutation 
would have been missed. 
 
Further screening will establish whether mutations in the PI(3,5)P2 
pathway contribute to these diseases.  CMT is a peripheral neuropathy that can 
affect sensory neurons, motor neurons, or both.  CMT is a spectrum of diseases.  
Related diseases include Hereditary Spastic Paraplegia (HSP), Amylateral 
Sclerosis (ALS), Distal Hereditary Motor Neuronopathy (dHMN), Hereditary 
Sensory Neuropathy (HSN), and Spinal Muscular Atrophy (SMA).  These 
diseases resemble CMT as they are genetically heterogeneous, overlap 
phenotypically with CMT, and can be caused by mutations in the same genes as 
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identified in CMT.  HSP is characterized by progressive, severe lower extremity 
spasticity caused by degeneration of the motor neurons in the corticospinal tracts 
(Fink et al., 1996).  ALS is characterized by loss of motor neurons in the brain, 
brainstem, and spinal cord, ultimately leading to paralysis (Pasinelli and Brown, 
2006).  dHMN is clinically similar to CMT, but results from degeneration of only 
spinal motor neurons (Irobi et al., 2006).  HSN  is also similar to CMT, but is 
limited to sensory neuron degeneration with no motor involvement (Auer-
Grumbach et al., 2006).  SMA is characterized by muscle atrophy and 
degeneration of spinal motor neurons (Monani, 2005).  All of these diseases 
display phenotypes that are observed in the pale tremor mouse.  
Phosphoinositide signaling pathways have been implicated in several of these 
diseases.   
 
Heterozygous mutations in FAB1 cause François-Neetens mouchetée 
fleck corneal dystrophy.  This suggests that heterozygous mutations in FIG4 and 
VAC14 may also cause a similar corneal dystrophy.  Heterozygous and 
homozygous Fig4 null mice do not display any corneal defects (Chow CY, 
unpublished observations).  Furthermore, there is no evidence of corneal 
dystrophy in the CMT4J patients.  To date, we have not screened any patients 
with corneal dystrophy.   
 
Massive neurodegeneration is observed in the pale tremor, Vac14 null, 
and ingls brain, indicating the importance of PI(3,5)P2 signaling in the CNS as 
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well as the PNS.  The ingls mouse has demonstrated that certain mutations in 
this pathway only affect brain function.  The PNS may be less sensitive to 
abnormal PI(3,5)P2 signaling.  Human neurodegenerative diseases that affect 
only the brain should be screened as well.  Diseases that include hydrocephalus 
and vacuolation of brain tissue (spongiform appearance) should be considered.  
Frontal Temporal Dementia (FTD) is the second most common form of dementia.  
FTD is characterized by spongiform degeneration of cortical regions and ventricle 
dilation (hydrocephalus) (Bugiani, 2007).  FTD is genetically heterogeneous and 
may be caused by mutations in the PI(3,5)P2 pathway.   
 
Concluding remarks 
The discovery of several spontaneous mouse mutants in PI(3,5)P2 
signaling has established the importance of PI(3,5)P2 in mammals.  Study of 
these mouse mutants led to identification of a new form of CMT caused by 
mutations in FIG4.  The future of PI(3,5)P2  research should utilize mouse and 
human genetics.  Both phenotype and genotype driven approaches will 
contribute to understanding the regulation and interactions of this pathway.  Work 
in the mouse will be accelerated if it is informed by the body of knowledge gained 
from yeast.  Continuing to screen human diseases for mutations in the PI(3,5)P2 
pathway will identify new mutations and crucial functions of these genes.  As we 
understand more about PI(3,5)P2 signaling, and identify more patients, we will 






Figure 5-1. PI(3,5)P2 pathway in yeast and mammals.  The PI(3,5)P2 pathway 
is well conserved in yeast and mammals.  Vac7 is a yeast specific activator of 
Fab1.  WIPI1-4 are mammalian homologs of Atg18.  it is unknown which if any of 
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* PI(3,5)P2 levels in response to hyperosmotic stress is normal if Vac7, Vac14 and Fig4 are present.  Without them, 




Table 5-3. Mutation screens with negative results 
 
disease number of samples 
genes 
screened source 
CMT 95 VAC14 Jim Lupski  (Baylor) 
Centronuclear 
Myopathy 9 FIG4 Jim Dowling (U of M) 




 VAC14 Raffaella Zannolli (UNISI) 
SCA4 1 VAC14 Louis Ptacek (UCSF) 
 
*With the exception of SCA4, all these disease should be screened for FAB1 
and the other genes in the PI(3,5)P2 pathway.
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Table 5-4. Novel nonsynonymous and protein truncating variants 
identified in human FIG4 
 






























# missense variants not included in (Chow et al., 2007) except I41T 
 
## unpublished study 
 
* I41T transgenic mouse is being studied (Chapter III) 
 
**R905C is the same variant found in mouse strain WSB/EiJ (Chapter III) 
 
Underlined variants have been tested in yeast vacuole assay  
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Table 5-5. Common nonsynonymous variants identified in human FIG4 
 
variant rs# minor allele freq 
c1090 A>T (M364L) rs2295837 0.04 
c1961 T>C (V654A) rs9885672 0.14 
 








Adamska, M., Billi, A. C., Cheek, S., and Meisler, M. H. (2005). Genetic 
interaction between Wnt7a and Lrp6 during patterning of dorsal and posterior 
structures of the mouse limb. Dev Dyn 233, 368-372. 
Andrade, M. A., and Bork, P. (1995). HEAT repeats in the Huntington's disease 
protein. Nat Genet 11, 115-116. 
Andrade, M. A., Perez-Iratxeta, C., and Ponting, C. P. (2001a). Protein repeats: 
structures, functions, and evolution. J Struct Biol 134, 117-131. 
Andrade, M. A., Petosa, C., O'Donoghue, S. I., Muller, C. W., and Bork, P. 
(2001b). Comparison of ARM and HEAT protein repeats. J Mol Biol 309, 1-18. 
Auer-Grumbach, M., Mauko, B., Auer-Grumbach, P., and Pieber, T. R. (2006). 
Molecular genetics of hereditary sensory neuropathies. Neuromolecular Med 8, 
147-158. 
Begley, M. J., Taylor, G. S., Brock, M. A., Ghosh, P., Woods, V. L., and Dixon, J. 
E. (2006). Molecular basis for substrate recognition by MTMR2, a myotubularin 
family phosphoinositide phosphatase. Proc Natl Acad Sci U S A 103, 927-932. 
Berger, P., Berger, I., Schaffitzel, C., Tersar, K., Volkmer, B., and Suter, U. 
(2006). Multi-level regulation of myotubularin-related protein-2 phosphatase 
activity by myotubularin-related protein-13/set-binding factor-2. Hum Mol Genet 
15, 569-579. 
Berger, P., Bonneick, S., Willi, S., Wymann, M., and Suter, U. (2002). Loss of 
phosphatase activity in myotubularin-related protein 2 is associated with Charcot-
Marie-Tooth disease type 4B1. Hum Mol Genet 11, 1569-1579. 
Bernard, R., De Sandre-Giovannoli, A., Delague, V., and Levy, N. (2006). 
Molecular genetics of autosomal-recessive axonal Charcot-Marie-Tooth 
neuropathies. Neuromolecular Med 8, 87-106. 
 
 130
Berti, C., Nodari, A., Wrabetz, L., and Feltri, M. L. (2006). Role of integrins in 
peripheral nerves and hereditary neuropathies. Neuromolecular Med 8, 191-204. 
Bolino, A., Bolis, A., Previtali, S. C., Dina, G., Bussini, S., Dati, G., Amadio, S., 
Del Carro, U., Mruk, D. D., Feltri, M. L., et al. (2004). Disruption of Mtmr2 
produces CMT4B1-like neuropathy with myelin outfolding and impaired 
spermatogenesis. J Cell Biol 167, 711-721. 
Bolino, A., Muglia, M., Conforti, F. L., LeGuern, E., Salih, M. A., Georgiou, D. M., 
Christodoulou, K., Hausmanowa-Petrusewicz, I., Mandich, P., Schenone, A., et 
al. (2000). Charcot-Marie-Tooth type 4B is caused by mutations in the gene 
encoding myotubularin-related protein-2. Nat Genet 25, 17-19. 
Bolis, A., Coviello, S., Bussini, S., Dina, G., Pardini, C., Previtali, S. C., Malaguti, 
M., Morana, P., Del Carro, U., Feltri, M. L., et al. (2005). Loss of Mtmr2 
phosphatase in Schwann cells but not in motor neurons causes Charcot-Marie-
Tooth type 4B1 neuropathy with myelin outfoldings. J Neurosci 25, 8567-8577. 
Bolis, A., Zordan, P., Coviello, S., and Bolino, A. (2007). Myotubularin-related 
(MTMR) phospholipid phosphatase proteins in the peripheral nervous system. 
Mol Neurobiol 35, 308-316. 
Bonangelino, C. J., Nau, J. J., Duex, J. E., Brinkman, M., Wurmser, A. E., Gary, 
J. D., Emr, S. D., and Weisman, L. S. (2002). Osmotic stress-induced increase of 
phosphatidylinositol 3,5-bisphosphate requires Vac14p, an activator of the lipid 
kinase Fab1p. J Cell Biol 156, 1015-1028. 
Bonifacino, J. S., and Traub, L. M. (2003). Signals for sorting of transmembrane 
proteins to endosomes and lysosomes. Annu Rev Biochem 72, 395-447. 
Bonneick, S., Boentert, M., Berger, P., Atanasoski, S., Mantei, N., Wessig, C., 
Toyka, K. V., Young, P., and Suter, U. (2005). An animal model for Charcot-
Marie-Tooth disease type 4B1. Hum Mol Genet 14, 3685-3695. 
Buchner, D. A., Trudeau, M., and Meisler, M. H. (2003). SCNM1, a putative RNA 
splicing factor that modifies disease severity in mice. Science 301, 967-969. 
Bugiani, O. (2007). The many ways to frontotemporal degeneration and beyond. 
Neurol Sci 28, 241-244. 
 
 131
Buoni, S., Zannolli, R., de Santi, M., Macucci, F., Hayek, J., Orsi, A., Scarinci, R., 
Buscalferri, A., Cuccia, A., Zappella, M., and Miracco, C. (2006). 
Neurocutaneous syndrome with mental delay, autism, blockage in intracellular 
vescicular trafficking and melanosome defects. Eur J Neurol 13, 842-851. 
Cassina, P., Cassina, A., Pehar, M., Castellanos, R., Gandelman, M., de Leon, 
A., Robinson, K. M., Mason, R. P., Beckman, J. S., Barbeito, L., and Radi, R. 
(2008). Mitochondrial dysfunction in SOD1G93A-bearing astrocytes promotes 
motor neuron degeneration: prevention by mitochondrial-targeted antioxidants. J 
Neurosci 28, 4115-4122. 
Chow, C. Y., Zhang, Y., Dowling, J. J., Jin, N., Adamska, M., Shiga, K., Szigeti, 
K., Shy, M. E., Li, J., Zhang, X., et al. (2007). Mutation of FIG4 causes 
neurodegeneration in the pale tremor mouse and patients with CMT4J. Nature 
448, 68-72. 
Cooke, F. T., Dove, S. K., McEwen, R. K., Painter, G., Holmes, A. B., Hall, M. N., 
Michell, R. H., and Parker, P. J. (1998). The stress-activated phosphatidylinositol 
3-phosphate 5-kinase Fab1p is essential for vacuole function in S. cerevisiae. 
Curr Biol 8, 1219-1222. 
Correa-Cerro, L. S., and Mandell, J. W. (2007). Molecular mechanisms of 
astrogliosis: new approaches with mouse genetics. J Neuropathol Exp Neurol 66, 
169-176. 
Delague, V., Jacquier, A., Hamadouche, T., Poitelon, Y., Baudot, C., Boccaccio, 
I., Chouery, E., Chaouch, M., Kassouri, N., Jabbour, R., et al. (2007). Mutations 
in FGD4 encoding the Rho GDP/GTP exchange factor FRABIN cause autosomal 
recessive Charcot-Marie-Tooth type 4H. Am J Hum Genet 81, 1-16. 
Di Giorgio, F. P., Carrasco, M. A., Siao, M. C., Maniatis, T., and Eggan, K. 
(2007). Non-cell autonomous effect of glia on motor neurons in an embryonic 
stem cell-based ALS model. Nat Neurosci 10, 608-614. 
Di Paolo, G., and De Camilli, P. (2006). Phosphoinositides in cell regulation and 
membrane dynamics. Nature 443, 651-657. 
Dove, S. K., and Johnson, Z. E. (2007). Our FABulous VACation: a decade of 
phosphatidylinositol 3,5-bisphosphate. Biochem Soc Symp, 129-139. 
 
 132
Dove, S. K., McEwen, R. K., Mayes, A., Hughes, D. C., Beggs, J. D., and Michell, 
R. H. (2002). Vac14 controls PtdIns(3,5)P(2) synthesis and Fab1-dependent 
protein trafficking to the multivesicular body. Curr Biol 12, 885-893. 
Dove, S. K., Piper, R. C., McEwen, R. K., Yu, J. W., King, M. C., Hughes, D. C., 
Thuring, J., Holmes, A. B., Cooke, F. T., Michell, R. H., et al. (2004). Svp1p 
defines a family of phosphatidylinositol 3,5-bisphosphate effectors. Embo J 23, 
1922-1933. 
Dubourg, O., Azzedine, H., Verny, C., Durosier, G., Birouk, N., Gouider, R., 
Salih, M., Bouhouche, A., Thiam, A., Grid, D., et al. (2006). Autosomal-recessive 
forms of demyelinating Charcot-Marie-Tooth disease. Neuromolecular Med 8, 75-
86. 
Duex, J. E., Nau, J. J., Kauffman, E. J., and Weisman, L. S. (2006a). 
Phosphoinositide 5-phosphatase Fig 4p is required for both acute rise and 
subsequent fall in stress-induced phosphatidylinositol 3,5-bisphosphate levels. 
Eukaryot Cell 5, 723-731. 
Duex, J. E., Tang, F., and Weisman, L. S. (2006b). The Vac14p-Fig4p complex 
acts independently of Vac7p and couples PI3,5P2 synthesis and turnover. J Cell 
Biol 172, 693-704. 
Escayg, A., MacDonald, B. T., Meisler, M. H., Baulac, S., Huberfeld, G., An-
Gourfinkel, I., Brice, A., LeGuern, E., Moulard, B., Chaigne, D., et al. (2000). 
Mutations of SCN1A, encoding a neuronal sodium channel, in two families with 
GEFS+2. Nat Genet 24, 343-345. 
Fink, J. K., Heiman-Patterson, T., Bird, T., Cambi, F., Dube, M. P., Figlewicz, D. 
A., Fink, J. K., Haines, J. L., Heiman-Patterson, T., Hentati, A., et al. (1996). 
Hereditary spastic paraplegia: advances in genetic research. Hereditary Spastic 
Paraplegia Working group. Neurology 46, 1507-1514. 
Flanigan, K., Gardner, K., Alderson, K., Galster, B., Otterud, B., Leppert, M. F., 
Kaplan, C., and Ptacek, L. J. (1996). Autosomal dominant spinocerebellar ataxia 
with sensory axonal neuropathy (SCA4): clinical description and genetic 
localization to chromosome 16q22.1. Am J Hum Genet 59, 392-399. 
Frazer, K. A., Wade, C. M., Hinds, D. A., Patil, N., Cox, D. R., and Daly, M. J. 
(2004). Segmental phylogenetic relationships of inbred mouse strains revealed 
 
 133
by fine-scale analysis of sequence variation across 4.6 mb of mouse genome. 
Genome Res 14, 1493-1500. 
Gary, J. D., Sato, T. K., Stefan, C. J., Bonangelino, C. J., Weisman, L. S., and 
Emr, S. D. (2002). Regulation of Fab1 phosphatidylinositol 3-phosphate 5-kinase 
pathway by Vac7 protein and Fig4, a polyphosphoinositide phosphatase family 
member. Mol Biol Cell 13, 1238-1251. 
Gary, J. D., Wurmser, A. E., Bonangelino, C. J., Weisman, L. S., and Emr, S. D. 
(1998). Fab1p is essential for PtdIns(3)P 5-kinase activity and the maintenance 
of vacuolar size and membrane homeostasis. J Cell Biol 143, 65-79. 
Houlden, H., and Reilly, M. M. (2006). Molecular genetics of autosomal-dominant 
demyelinating Charcot-Marie-Tooth disease. Neuromolecular Med 8, 43-62. 
Hughes, W. E., Cooke, F. T., and Parker, P. J. (2000). Sac phosphatase domain 
proteins. Biochem J 350 Pt 2, 337-352. 
Ikonomov, O. C., Sbrissa, D., Mlak, K., Kanzaki, M., Pessin, J., and Shisheva, A. 
(2002a). Functional dissection of lipid and protein kinase signals of PIKfyve 
reveals the role of PtdIns 3,5-P2 production for endomembrane integrity. J Biol 
Chem 277, 9206-9211. 
Ikonomov, O. C., Sbrissa, D., Mlak, K., and Shisheva, A. (2002b). Requirement 
for PIKfyve enzymatic activity in acute and long-term insulin cellular effects. 
Endocrinology 143, 4742-4754. 
Ikonomov, O. C., Sbrissa, D., and Shisheva, A. (2001). Mammalian cell 
morphology and endocytic membrane homeostasis require enzymatically active 
phosphoinositide 5-kinase PIKfyve. J Biol Chem 276, 26141-26147. 
Irobi, J., Dierick, I., Jordanova, A., Claeys, K. G., De Jonghe, P., and 
Timmerman, V. (2006). Unraveling the genetics of distal hereditary motor 
neuronopathies. Neuromolecular Med 8, 131-146. 
Kearney, J. A., Wiste, A. K., Stephani, U., Trudeau, M. M., Siegel, A., 
RamachandranNair, R., Elterman, R. D., Muhle, H., Reinsdorf, J., Shields, W. D., 
et al. (2006). Recurrent de novo mutations of SCN1A in severe myoclonic 
epilepsy of infancy. Pediatr Neurol 34, 116-120. 
 
 134
Kennedy, M. J., and Ehlers, M. D. (2006). Organelles and Trafficking Machinery 
for Postsynaptic Plasticity. Annu Rev Neurosci. 
Kleopa, K. A., and Scherer, S. S. (2006). Molecular genetics of X-linked Charcot-
Marie-Tooth disease. Neuromolecular Med 8, 107-122. 
Kohrman, D. C., Harris, J. B., and Meisler, M. H. (1996). Mutation detection in the 
med and medJ alleles of the sodium channel Scn8a. Unusual splicing due to a 
minor class AT-AC intron. J Biol Chem 271, 17576-17581. 
Lemaire, J. F., and McPherson, P. S. (2006). Binding of Vac14 to neuronal nitric 
oxide synthase: Characterisation of a new internal PDZ-recognition motif. FEBS 
Lett. 
Lemmon, M. A. (2003). Phosphoinositide recognition domains. Traffic 4, 201-
213. 
Li, J., Bai, Y., Ghandour, K., Qin, P., Grandis, M., Trostinskaia, A., Ianakova, E., 
Wu, X., Schenone, A., Vallat, J. M., et al. (2005a). Skin biopsies in myelin-related 
neuropathies: bringing molecular pathology to the bedside. Brain 128, 1168-
1177. 
Li, J., Bai, Y., Ianakova, E., Grandis, M., Uchwat, F., Trostinskaia, A., Krajewski, 
K. M., Garbern, J., Kupsky, W. J., and Shy, M. E. (2006). Major myelin protein 
gene (P0) mutation causes a novel form of axonal degeneration. J Comp Neurol 
498, 252-265. 
Li, S., Tiab, L., Jiao, X., Munier, F. L., Zografos, L., Frueh, B. E., Sergeev, Y., 
Smith, J., Rubin, B., Meallet, M. A., et al. (2005b). Mutations in PIP5K3 are 
associated with Francois-Neetens mouchetee fleck corneal dystrophy. Am J Hum 
Genet 77, 54-63. 
Liu, S. H., Marks, M. S., and Brodsky, F. M. (1998). A dominant-negative clathrin 
mutant differentially affects trafficking of molecules with distinct sorting motifs in 
the class II major histocompatibility complex (MHC) pathway. J Cell Biol 140, 
1023-1037. 
Lupski, J. R., de Oca-Luna, R. M., Slaugenhaupt, S., Pentao, L., Guzzetta, V., 
Trask, B. J., Saucedo-Cardenas, O., Barker, D. F., Killian, J. M., Garcia, C. A., et 
 
 135
al. (1991). DNA duplication associated with Charcot-Marie-Tooth disease type 
1A. Cell 66, 219-232. 
Maksakova, I. A., Romanish, M. T., Gagnier, L., Dunn, C. A., van de Lagemaat, 
L. N., and Mager, D. L. (2006). Retroviral elements and their hosts: insertional 
mutagenesis in the mouse germ line. PLoS Genet 2, e2. 
Marks, M. S. (2008). FIG4, Charcot-Marie-Tooth disease, and hypopigmentation: 
a role for phosphoinositides in melanosome biogenesis? Pigment Cell Melanoma 
Res 21, 11-14. 
Marks, M. S., and Seabra, M. C. (2001). The melanosome: membrane dynamics 
in black and white. Nat Rev Mol Cell Biol 2, 738-748. 
Martyn, C. N., and Hughes, R. A. (1997). Epidemiology of peripheral neuropathy. 
J Neurol Neurosurg Psychiatry 62, 310-318. 
McKinney, B. C., Chow, C. Y., Meisler, M. H., and Murphy, G. G. (2008). 
Exaggerated emotional behavior in mice heterozygous null for the sodium 
channel Scn8a (Na1.6). Genes Brain Behav. 
McNiven, M. A. (2005). Dynamin in disease. Nat Genet 37, 215-216. 
Michell, R. H., Heath, V. L., Lemmon, M. A., and Dove, S. K. (2006). 
Phosphatidylinositol 3,5-bisphosphate: metabolism and cellular functions. Trends 
Biochem Sci 31, 52-63. 
Monani, U. R. (2005). Spinal muscular atrophy: a deficiency in a ubiquitous 
protein; a motor neuron-specific disease. Neuron 48, 885-896. 
Naef, R., and Suter, U. (1998). Many facets of the peripheral myelin protein 
PMP22 in myelination and disease. Microsc Res Tech 41, 359-371. 
Nagai, M., Re, D. B., Nagata, T., Chalazonitis, A., Jessell, T. M., Wichterle, H., 
and Przedborski, S. (2007). Astrocytes expressing ALS-linked mutated SOD1 
release factors selectively toxic to motor neurons. Nat Neurosci 10, 615-622. 
 
 136
Nicot, A. S., Fares, H., Payrastre, B., Chisholm, A. D., Labouesse, M., and 
Laporte, J. (2006). The Phosphoinositide Kinase PIKfyve/Fab1p Regulates 
Terminal Lysosome Maturation in Caenorhabditis elegans. Mol Biol Cell 17, 
3062-3074. 
Niemann, A., Berger, P., and Suter, U. (2006). Pathomechanisms of mutant 
proteins in Charcot-Marie-Tooth disease. Neuromolecular Med 8, 217-242. 
Niwa, H., Yamamura, K., and Miyazaki, J. (1991). Efficient selection for high-
expression transfectants with a novel eukaryotic vector. Gene 108, 193-199. 
Oliver, P. L., Bitoun, E., and Davies, K. E. (2007). Comparative genetic analysis: 
the utility of mouse genetic systems for studying human monogenic disease. 
Mamm Genome 18, 412-424. 
Pareyson, D., Scaioli, V., and Laura, M. (2006). Clinical and electrophysiological 
aspects of Charcot-Marie-Tooth disease. Neuromolecular Med 8, 3-22. 
Park, M., Salgado, J. M., Ostroff, L., Helton, T. D., Robinson, C. G., Harris, K. M., 
and Ehlers, M. D. (2006). Plasticity-induced growth of dendritic spines by 
exocytic trafficking from recycling endosomes. Neuron 52, 817-830. 
Pasinelli, P., and Brown, R. H. (2006). Molecular biology of amyotrophic lateral 
sclerosis: insights from genetics. Nat Rev Neurosci 7, 710-723. 
Pierson, C. R., Tomczak, K., Agrawal, P., Moghadaszadeh, B., and Beggs, A. H. 
(2005). X-linked myotubular and centronuclear myopathies. J Neuropathol Exp 
Neurol 64, 555-564. 
Previtali, S. C., Quattrini, A., and Bolino, A. (2007). Charcot-Marie-Tooth type 4B 
demyelinating neuropathy: deciphering the role of MTMR phosphatases. Expert 
Rev Mol Med 9, 1-16. 
Raeymaekers, P., Timmerman, V., Nelis, E., De Jonghe, P., Hoogendijk, J. E., 
Baas, F., Barker, D. F., Martin, J. J., De Visser, M., Bolhuis, P. A., and et al. 
(1991). Duplication in chromosome 17p11.2 in Charcot-Marie-Tooth neuropathy 
type 1a (CMT 1a). The HMSN Collaborative Research Group. Neuromuscul 
Disord 1, 93-97. 
 
 137
Rainier, S., Sher, C., Reish, O., Thomas, D., and Fink, J. K. (2006). De novo 
occurrence of novel SPG3A/atlastin mutation presenting as cerebral palsy. Arch 
Neurol 63, 445-447. 
Raposo, G., and Marks, M. S. (2007). Melanosomes--dark organelles enlighten 
endosomal membrane transport. Nat Rev Mol Cell Biol 8, 786-797. 
Robinson, F. L., and Dixon, J. E. (2006). Myotubularin phosphatases: policing 3-
phosphoinositides. Trends Cell Biol 16, 403-412. 
Robinson, F. L., Niesman, I. R., Beiswenger, K. K., and Dixon, J. E. (2008). Loss 
of the inactive myotubularin-related phosphatase Mtmr13 leads to a Charcot-
Marie-Tooth 4B2-like peripheral neuropathy in mice. Proc Natl Acad Sci U S A. 
Rudge, S. A., Anderson, D. M., and Emr, S. D. (2004). Vacuole size control: 
regulation of PtdIns(3,5)P2 levels by the vacuole-associated Vac14-Fig4 
complex, a PtdIns(3,5)P2-specific phosphatase. Mol Biol Cell 15, 24-36. 
Rusten, T. E., Rodahl, L. M., Pattni, K., Englund, C., Samakovlis, C., Dove, S., 
Brech, A., and Stenmark, H. (2006). Fab1 phosphatidylinositol 3-phosphate 5-
kinase controls trafficking but not silencing of endocytosed receptors. Mol Biol 
Cell 17, 3989-4001. 
Rutherford, A. C., Traer, C., Wassmer, T., Pattni, K., Bujny, M. V., Carlton, J. G., 
Stenmark, H., and Cullen, P. J. (2006). The mammalian phosphatidylinositol 3-
phosphate 5-kinase (PIKfyve) regulates endosome-to-TGN retrograde transport. 
J Cell Sci 119, 3944-3957. 
Sbrissa, D., Ikonomov, O. C., Deeb, R., and Shisheva, A. (2002). 
Phosphatidylinositol 5-phosphate biosynthesis is linked to PIKfyve and is 
involved in osmotic response pathway in mammalian cells. J Biol Chem 277, 
47276-47284. 
Sbrissa, D., Ikonomov, O. C., Fu, Z., Ijuin, T., Gruenberg, J., Takenawa, T., and 
Shisheva, A. (2007). Core protein machinery for mammalian phosphatidylinositol 
3,5-bisphosphate synthesis and turnover that regulates the progression of 
endosomal transport. Novel Sac phosphatase joins the ArPIKfyve-PIKfyve 
complex. J Biol Chem 282, 23878-23891. 
 
 138
Schmitt-John, T., Drepper, C., Mussmann, A., Hahn, P., Kuhlmann, M., Thiel, C., 
Hafner, M., Lengeling, A., Heimann, P., Jones, J. M., et al. (2005). Mutation of 
Vps54 causes motor neuron disease and defective spermiogenesis in the 
wobbler mouse. Nat Genet 37, 1213-1215. 
Schroder, J. M. (2006). Neuropathology of Charcot-Marie-Tooth and related 
disorders. Neuromolecular Med 8, 23-42. 
Schymick, J. C., Talbot, K., and Traynor, B. J. (2007). Genetics of sporadic 
amyotrophic lateral sclerosis. Hum Mol Genet 16 Spec No. 2, R233-242. 
Senderek, J., Bergmann, C., Weber, S., Ketelsen, U. P., Schorle, H., Rudnik-
Schoneborn, S., Buttner, R., Buchheim, E., and Zerres, K. (2003). Mutation of the 
SBF2 gene, encoding a novel member of the myotubularin family, in Charcot-
Marie-Tooth neuropathy type 4B2/11p15. Hum Mol Genet 12, 349-356. 
Snipes, G. J., Suter, U., Welcher, A. A., and Shooter, E. M. (1992). 
Characterization of a novel peripheral nervous system myelin protein (PMP-
22/SR13). J Cell Biol 117, 225-238. 
Stendel, C., Roos, A., Deconinck, T., Pereira, J., Castagner, F., Niemann, A., 
Kirschner, J., Korinthenberg, R., Ketelsen, U., Battaloglu, E., et al. (2007a). 
Peripheral nerve demyelination caused by a mutant Rho GTPase guanine 
nucleotide exchange factor, frabin/FGD4. Am J Hum Genet, preprint. 
Stendel, C., Roos, A., Deconinck, T., Pereira, J., Castagner, F., Niemann, A., 
Kirschner, J., Korinthenberg, R., Ketelsen, U. P., Battaloglu, E., et al. (2007b). 
Peripheral nerve demyelination caused by a mutant Rho GTPase guanine 
nucleotide exchange factor, frabin/FGD4. Am J Hum Genet 81, 158-164. 
Strahl, T., and Thorner, J. (2007). Synthesis and function of membrane 
phosphoinositides in budding yeast, Saccharomyces cerevisiae. Biochim Biophys 
Acta 1771, 353-404. 
Suter, U. (2007). Phosphoinositides and Charcot-Marie-tooth disease: new keys 
to old questions. Cell Mol Life Sci 64, 3261-3265. 
Szigeti, K., Garcia, C. A., and Lupski, J. R. (2006). Charcot-Marie-Tooth disease 
and related hereditary polyneuropathies: molecular diagnostics determine 
aspects of medical management. Genet Med 8, 86-92. 
 
 139
Tersar, K., Boentert, M., Berger, P., Bonneick, S., Wessig, C., Toyka, K. V., 
Young, P., and Suter, U. (2007). Mtmr13/Sbf2-deficient mice: an animal model 
for CMT4B2. Hum Mol Genet 16, 2991-3001. 
Umikawa, M., Obaishi, H., Nakanishi, H., Satoh-Horikawa, K., Takahashi, K., 
Hotta, I., Matsuura, Y., and Takai, Y. (1999). Association of frabin with the actin 
cytoskeleton is essential for microspike formation through activation of Cdc42 
small G protein. J Biol Chem 274, 25197-25200. 
Valentijn, L. J., Baas, F., Wolterman, R. A., Hoogendijk, J. E., van den Bosch, N. 
H., Zorn, I., Gabreels-Festen, A. W., de Visser, M., and Bolhuis, P. A. (1992). 
Identical point mutations of PMP-22 in Trembler-J mouse and Charcot-Marie-
Tooth disease type 1A. Nat Genet 2, 288-291. 
Verhoeven, K., De Jonghe, P., Coen, K., Verpoorten, N., Auer-Grumbach, M., 
Kwon, J. M., FitzPatrick, D., Schmedding, E., De Vriendt, E., Jacobs, A., et al. 
(2003). Mutations in the small GTP-ase late endosomal protein RAB7 cause 
Charcot-Marie-Tooth type 2B neuropathy. Am J Hum Genet 72, 722-727. 
Volpicelli-Daley, L., and De Camilli, P. (2007). Phosphoinositides' link to 
neurodegeneration. Nat Med 13, 784-786. 
Vowels, J. J., and Payne, G. S. (1998). A dileucine-like sorting signal directs 
transport into an AP-3-dependent, clathrin-independent pathway to the yeast 
vacuole. Embo J 17, 2482-2493. 
Walker, F. O. (2007). Huntington's Disease. Semin Neurol 27, 143-150. 
Wallengren, J. (2005). Neuroanatomy and neurophysiology of itch. Dermatol 
Ther 18, 292-303. 
Yamanaka, K., Chun, S. J., Boillee, S., Fujimori-Tonou, N., Yamashita, H., 
Gutmann, D. H., Takahashi, R., Misawa, H., and Cleveland, D. W. (2008). 
Astrocytes as determinants of disease progression in inherited amyotrophic 
lateral sclerosis. Nat Neurosci 11, 251-253. 
Zannolli, R., Buoni, S., de Santi, M., Miracco, C., Vonella, G., Tassini, M., Vivi, 
A., Viviano, M., Rossi, T., Orsi, A., et al. (2008). New neurocutaneous syndrome 




Zhang, X., Chow, C. Y., Sahenk, Z., Shy, M. E., Meisler, M. H., and Li, J. (2008). 
Mutation of FIG4 in patients causes a rapidly progressive, asymmetric neuronal 
degeneration. Brain, in press. 
Zhang, Y., Zolov, S. N., Chow, C. Y., Slutsky, S. G., Richardson, S. C., Piper, R. 
C., Yang, B., Nau, J. J., Westrick, R. J., Morrison, S. J., et al. (2007). Loss of 
Vac14, a regulator of the signaling lipid phosphatidylinositol 3,5-bisphosphate, 
results in neurodegeneration in mice. Proc Natl Acad Sci U S A 104, 17518-
17523. 
Zhang, Y. W., and Xu, H. (2007). Molecular and cellular mechanisms for 
Alzheimer's disease: understanding APP metabolism. Curr Mol Med 7, 687-696. 
Zuchner, S., Noureddine, M., Kennerson, M., Verhoeven, K., Claeys, K., De 
Jonghe, P., Merory, J., Oliveira, S. A., Speer, M. C., Stenger, J. E., et al. (2005). 
Mutations in the pleckstrin homology domain of dynamin 2 cause dominant 
intermediate Charcot-Marie-Tooth disease. Nat Genet 37, 289-294. 
Zuchner, S., and Vance, J. M. (2006). Molecular genetics of autosomal-dominant 
axonal Charcot-Marie-Tooth disease. Neuromolecular Med 8, 63-74. 
 
 
